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Abstract 
 
Candida albicans is an opportunistic pathogen, which is responsible for causing 
systemic infection in immunocompromised patients in hospital settings (nosocomial 
infections).  90% of these nosocomial fungal infections are caused by C. albicans, and 
the estimated annual cost of treating them exceeds $1 billion per year.  Despite this 
expenditure, there is a high mortality rate of 50%.  There are two main routes of 
infections, first a mucosal infection that can spread and invades deeper into the tissues 
and gets disseminated into the bloodstream. Second, more frequently seen in hospital 
settings, is when Candida cells dislodge from a biofilm that has formed on intravenous 
devices or catheters.  Treatment of these diseases is difficult due to a dearth of 
antifungal drugs and new strategies are required to explore mechanisms used by 
Candida in causing infection.  
One way of approaching these significant scientific challenges is to identify virulence 
determinants and mechanisms, which apart from providing insightful knowledge of 
fungal pathogenesis, can also be used as targets for antifungal drug development.   The 
innate immune responses in humans, which are important for defense against fungal 
infections, are conserved in Caenorhabditis elegans.  In order to identify Candida 
virulence factors, I have developed a C. elegans based pathogenesis assay, where 
nematodes were infected with fungi (both S. cerevisiae and C. albicans) and observed 
for disease phenotypes including death.  This assay can be used to study several 
aspects of disease progression in worms from swelling (inflammation a bio-marker of 
x 
 
infection) to colonization in the intestine, leading to intestinal distension and ultimately 
death of the host worm.   
The assay offers a fast and simple way of identifying unknown genes, which when 
established as a virulence determinant in the worm model, can be further studied in 
mammalian models.  I demonstrate the utility of this assay in multiple ways.  First as 
proof of principle using this assay I have identified a fungal mutant cap1, which is 
susceptible to reactive oxygen species (ROS), and fails to cause disease, except in bli-3 
mutant worms that carry a mutation in an oxidase gene and is responsible for the 
oxidative stress.  Second, we screened a library of ~1200 C. albicans mutants, and 
identified 7 genes, 3 known (CMP1, IFF11 and SAP 8), validating the assay and 4 novel 
genes (orf19.1219, orf19.6713, DOT4 and ZCF15) that play a role in fungal infection.   
Third use of this assay is to test potential drugs in a high throughput fashion.  Families 
of related compounds were identified through a screen of 30,000 compounds, for their 
ability as potential inhibitors of C. albicans adhesion to biological and inert surfaces.  
These compounds were further tested in this assay for their ability to reduce infection of 
C. albicans in worms. The assay provides us with a method to test efficacy of 
antifungals in vivo. Finally, using the survival assay, a test for mortality caused by 
infection, we can observe disparity in the different C. albicans fluconazole resistant 
strains isolated from AIDS patients.  In addition this assay after small modification can 
be potentially employed to screen the C. elegans RNAi library to identify the modulators 
of innate immune responses during fungal infection. 
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Chapter 1 
Introduction  
1.1  Effects of fungal pathogens on humans 
Fungal organisms have a huge impact on humans either from their beneficial uses in 
food and pharmaceutical industries or from the harmful effects of the pathogens.  In the 
food industry different genera of fungus are used for different purposes, for example 
Baker’s yeast or Saccharomyces cerevisiae has been used for making breads and to 
produce alcoholic beverages while others like Agaricus bisporus (button or Portobello 
mushroom) or truffles are eaten directly.  In the pharmaceutical industry, fungi are used 
to produce antibiotics like Penicillin, Cyclosporin, Fusidic acid and others.  Other than 
these favorable uses, fungi can also be pathogenic to humans.  For the purpose of this 
thesis I am focused on role of fungus as a pathogen.  The dire effects of fungal 
organisms can be felt by humans either directly, through infection or indirectly when 
their ecosystem is affected by fungal infections.  There are many different genera of 
fungi that can cause infection in humans, plants and animals and these can have huge 
medical and economic6 impacts. 
Fungal pathogens that impact agriculture are diverse.  For example Magnaporthe 
oryzae causes rice blast in rice plants (COUCH et al. 2005) while Fusarium oxysporum 
targets multiple crops like tomatoes, sweet potatoes and was also responsible for 
causing Panama disease in banana plants (PLOETZ 2006). Apart from these, Ustilago 
maydis and Cochliobolus heterostrophus target maize (KÄMPER et al. 2006; LEV et al. 
1999)  while Alternaria alternata mainly targets citrus plants (PEEVER et al. 2000).  As for 
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the direct effect of fungal organisms, people in their daily lives suffer from mild fungal 
infections such as thrush and athlete’s foot. These infections are not life threatening and 
are relatively easy to manage, but difficult to cure.  On the other hand, patients who are 
immunocompromised can get fungal infections as a consequence of AIDS, undergoing 
organ transplants, or using intravenous devices and catheters.  These infections can 
range anywhere from mild to lethal.  The frequency of nosocomial (hospital acquired) 
fungal infections have increased since the last decade. The fungal genera mainly 
involved in causing nosocomial diseases in humans are Candida, Cryptococcus and 
Aspergillus.  For Cryptococcus and Aspergillus, C. neoformans, C. gattii and A. 
fumigatus are the medically relevant fungal organisms.  Many different species of 
Candida are involved in causing infections including C. albicans, C. tropicalis, C. krusei, 
C. dubliniensis, C. parapsilosis and C. glabrata.  Mortality rates of ~40% are seen in the 
patients suffering from infection due to these Candida species (HORN et al. 2009; 
WISPLINGHOFF et al. 2004).  Candida albicans causes 46% of all nosocomial Candida 
infections (Figure 1) (HORN et al. 2009).  
 
 
 
 
 
Figure 1. Distribution of Candida species isolated from 2019 patients with candidemia. 
3 
 
Some, but not all, of these different genera and species of fungi share common 
pathways in causing infection, such as Yap1, a transcription factor (Table 1).  Yap1 
belongs to a Yap family of 8 bZip proteins in S. cerevisiae (FERNANDES et al. 1997).  
This family is found only in fungi, as it binds to a specific DNA binding site containing 
TTA half site and central C-G pair (TTACTAA).  This binding site is distinct in two 
positions when compared to the DNA binding site of AP-1 proteins which is a TGA half 
site with a central C-G pair (TGACTCA) (FERNANDES et al. 1997).   In some cases the 
difference is only in 1 position.  In order to maintain this specificity, the amino acid 
residue that are directly involved in the interaction with this DNA binding site are also 
different when compared to other AP-1 proteins but are mostly conserved within Yap 
family of proteins. 
Yap1 binds to the above mentioned conserved sequence which is referred to as yAP-1 
response element (YRE), and is present within the promoter of its targets and activates 
their transcription (WEMMIE et al. 1994).  Yap1 has been implicated in resistance against 
variety of toxicants like cycloheximide (CYH), 4-nitroquinoline N-oxide (4-NQO), and 
cadmium, resistance against oxidative stress and multidrug resistance (MDR).  Some of 
the targets of Yap1 include cadmium resistance ATP binding cassette (ABC) transporter 
gene YCF1 (LI et al. 1997) as well as genes involved in oxidative stress response like 
GSH1, encoding gamma glutamylcysteine synthase (WU and MOYE-ROWLEY 1994), 
TRX2, encoding for thioredoxin (KUGE and JONES 1994), and GLR1, encoding for 
glutathione reductase (GRANT et al. 1996).  Yap1 also controls the expression of FLZ1, 
encoding for a multidrug transporter belonging to the major facilitator (MF) superfamily 
(ALARCO et al. 1997a).   Thus we can learn about these common mechanisms by 
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studying a few specific pathogens and since Yap1 and its homologs are fungal specific 
they can act as good targets for development of broad spectrum antifungals. 
 
Table 1. Homologs of Yap1 and their role in pathogenicity 
Organism Orthologs 
Requirement 
for virulence 
Reference 
Alternaria alternate AaAP1 Y (LIN et al. 2009) 
Aspergillus 
fumigatus 
Afyap1 N (LESSING et al. 2007) 
Candida glabrata CgAP1 N (CHEN et al. 2007) 
Cochliobolus 
heterostophus 
ChAP1 N (LEV et al. 2005b) 
Saccharomyces 
cerevisiae 
Yap1, Yap2  
(JAIN et al. 2009) 
This study 
Candida albicans Cap1  This study 
Aspergillus 
parasiticus 
ApyapA Y (REVERBERI et al. 2008) 
Ustilago maydis Yap1 Y (MOLINA and KAHMANN 2007) 
Magnaporthe 
grisea 
Moap1 Y (GUO et al. 2011) 
 
 
1.2 Candida albicans Threat 
In the last few decades, the incidence of nosocomial fungal infections especially 
candidemia has increased by 500% in large teaching hospitals and ~ 370% in small 
teaching and large nonteaching  hospitals (PFALLER 1996).  The rise in these cases of 
fungal infections is due to multiple reasons.  These include disruption of normal balance 
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in the microbiota of the patient due to the use of broad spectrum antibiotics and,  the 
increase in the number of immunocompromised patients who are either suffering from 
AIDS, are on immunosuppressants for transplants or undergoing chemotherapy  and 
finally due to dearth of antifungal therapies.    90% of these infections are caused by 
Candida species (FRIDKIN and JARVIS 1996) and 50%  of these infections are fatal 
(GUDLAUGSSON et al. 2003).   
Two main types of infection are caused by these species, namely mucosal and 
systemic.  Mucosal infection affects areas lined by epithelial cells including the mouth, 
upper gastrointestinal and uro-gential tract.   At least 75% of women have at least one 
episode of vaginitis caused by Candida in their lifetime (SOBEL 1988), and there are 
approximately 13 million cases reported annually in the United States (KENT 1991).  On 
the other hand, bloodstream infection (BSI), to some degree, is caused by the ability of 
this organism to form biofilms on intravenous devices and catheters (RICHARDS et al. 
2000; VELASCO et al. 2000; WISPLINGHOFF et al. 2003).  Among all BSI reported in US, 
Candida albicans is the fourth leading cause (EDMOND et al. 1999), resulting in 
approximately 5000 deaths per year (MORGAN et al. 2005), making it an important 
pathogen to study.   
 
1.3 Antifungals available for treatment 
Six main classes of drugs are currently available for treatment of fungal infections.  Four 
classes of these drugs, target the outer structures of the fungal cell, while the fifth type 
of drug Flucytosine, targets DNA and RNA synthesis in the fungal cell (Figure 2). The 
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first class are the Azoles, for example fluconazole, which inhibits the synthesis of 
ergosterol by inhibiting the enzyme cytochrome P450 14α demethylase (HITCHCOCK et 
al. 1990).  Ergosterol, a steroid alcohol, serves the same function in fungal membrane 
as cholesterol does in animal cell membrane.  It is required to maintain membrane 
permeability and fluidity.  Fluconazole is a fungistatic and is the drug most widely used 
against fungal infections.  Due to its widespread use, drug resistance to the azoles has 
evolved in Candida.   
 
Figure 2. Fungal cell and the targets for five classes of antifungals (KATZUNG et al. 
2009) 
The second class of drugs less commonly used than the azoles are Allylamines like 
Naftifine or Terbinfine which also target ergosterol synthesis.  They do this by inhibiting 
squalene monooxygenase (RYDER and DUPONT 1985).  The third class of antimycotics, 
is the Polyenes such as Amphotericin B, which compromises the cell membrane by 
binding directly to ergosterol (BRAJTBURG et al. 1990).  Polyenes do not have 
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widespread use but are the drug of choice for systemic infections.  Another important 
class of drugs is the Echinocandins such as Caspofungin, which targets β 1, 3 glucan 
synthase, the enzyme that  synthesizes β glucan, the main component of the fungal cell 
wall (MORRIS and VILLMANN 2006).   
The final drug is Sordarin, which specifically target C. albicans elongation factor 2 
(DOMÍNGUEZ et al. 1999), thus affecting protein synthesis.  Despite the availability of 
these drugs for treatment there is an increasing demand for new drugs due to the 
toxicity caused by these drugs. For example, at high doses, fluconazole affects 
cholesterol synthesis – a component of human cell membranes (HITCHCOCK et al. 1990). 
Most of all, repeated use of these drugs has led to increased pathogen resistance to 
these drugs by different mechanisms [reviewed in (GHANNOUM and RICE 1999)].  Thus, 
there is an immediate need for identification of novel virulence factors that could be 
targeted for development of new drug therapies.  
 
1.4 Methods to identify virulence factors 
Virulence factors may be identified using a candidate gene approach.  In this method, 
genes whose lose of function has been demonstrated to decrease virulence in vitro or in 
a model organism are specifically studied in a pathogen.  This method requires previous 
knowledge of gene function and a testable hypothetical role in virulence.  It allows for a 
thorough investigation of the suspected genes and a chance to learn more about them.  
The problem with this method is that it has limited potential for identification of novel 
factors.  Another approach is the use of an unbiased mutant screen using a phenotypic 
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readout for virulence.  Through such screens, genes that are responsible for that 
specific phenotype can be discovered, and thus their role as a virulence factor, can be 
identified.  This may also help in identifying novel mechanisms or pathways that the 
pathogen uses during infection.  A thorough investigation of the targets has to be done 
after an unbiased screen as loss of some nonessential genes can affect the organism in 
ways unrelated to virulence.  Researchers need to devise a systemic approach to 
prioritize subsequent gene analysis.  The disadvantage of this approach is that whole 
genome screens are not possible to conduct in most pathogens. 
 
1.5 Steps involved in fungal pathogenesis 
In order to cause disease, fungi need to adhere to specific surfaces, resist the host’s 
innate immune responses and then proliferate and spread into the host body.  Even 
though the order of these events is universal, there are other factors that can put 
pressure on pathogen survival in vivo (Figure 3).   
 
Figure 3. Factors affecting pathogen fitness in vivo. 
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Fungi employ diverse strategies to overcome these factors and cause disease. These 
strategies mainly involve sensing and responding to the environmental cues originating 
in the host niche.  There are many different types of virulence determinants involved in 
these processes.  The steps involved in initial stages of infection is adhesion, 
morphogenetic switching, invasion and in some cases phenotypic switching. 
 
1.5.1 Adhesion 
The initial step of adhesion is the recognition of host epithelial cells by the pathogen 
followed by attachment.  The fungal cell is the major host determinant in this step.  It is 
a dynamic structure whose architecture and composition is under the control of complex 
regulatory networks.  β glucans are the main components of the cell wall with a chitin 
inside an outer mannan layer (Figure 4).  
 
Figure 4.  Cell wall architecture of Candida albicans. (GOW et al. 2012).  
 
The mannan layer consists of heavily glycosylated mannoproteins secreted from the cell 
surface, and is mainly involved in cell-cell recognition.  These mannoproteins are 
covalently linked to the β 1-3 glucans directly, or through β 1-6 glucans  (CHAFFIN et al. 
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1998).  The biomolecules that promote the adhesion of fungal cells to host cells or cell 
ligands are referred to as adhesins (CALDERONE and FONZI 2001).  These adhesins are 
potent immnunogens in host organisms.  Some of the genes that code for these host-
recognition proteins are the cell wall proteins belonging to the ALS (Agglutinin Like 
Sequence) family (CHAFFIN 2008).  Currently, a vaccine against ALS3 is under clinical 
trials (LIU and FILLER 2011).  Proteins involved in maintaining cell wall composition are 
also equally important for the adherence of Candida to the host surface. 
 
1.5.2 Morphogenetic Switching 
Candida albicans is a dimorphic fungus as it can switch between the ovoid yeast forms 
and the elongated filamentous form.  The filamentous form consists of extended tube 
like structures called hyphae or elongated cells which are considered pseudohyphae 
(Figure 5). These pseudohyphae coexist with the other two forms in cultures and are 
also found during infections (SUDBERY et al. 2004).  For a long time it was believed that 
the filamentous form was the main requirement for virulence.  Since then it has been 
shown that virulence is attenuated in mutants that are locked in either the yeast form or 
the filamentous form (MITCHELL 1998).  This indicates that morphological switching is 
important during the process of pathogenesis.  The ability of the organism to switch 
between the yeast and filamentous forms presumably allows the organism to invade a 
variety of body locations, adjust quickly to changes in host environment, evade immune 
responses and counteract drug therapies (CALDERONE 2002).   
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Figure 5. Different morphologies of C. albicans.  (A) Budding yeast, (B) Psuedohyphal 
growth and (C) Hyphal growth. 
Apart from many different proteins and cues that affect morphogenesis, 4 main 
pathways are involved in the process: Efg1, Cph1, Hog1 and PKC pathways.  Efg1 and 
Cph1 are transcription factors, while Hog 1 and PKC are Map Kinase and Protein 
Kinase respectively.  Morphogenetic switching is under the control of network of 
regulatory proteins which behave differently depending on the environmental niche and 
cues.  For example in case of PHR1 and PHR2 which encode a glycosidase, the 
virulence phenotype of a phr1 null mutant is attenuated in systemic infections but not in 
vaginal infections.  In contrast phr2 null mutants are virulent in systemic situation but 
avirulent in vaginal infection model (DE BERNARDIS et al. 1998; SAPORITO-IRWIN et al. 
1995) 
 
1.5.3 Invasion 
Adherence of the fungal cell to the host surface is followed by invasion into the host 
tissue.  Epithelial cell invasion is important for mucosal candidiasis since mutants 
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lacking this ability in vitro are not able to confer virulence in animal models.  Invasion is 
usually carried out by two distinct mechanisms (Figure 6).  Either the fungal cell induces 
endocytosis in host cell or it penetrates into or between the host cells (DALLE et al. 2010; 
VILLAR et al. 2007). (DALLE et al. 2010)(DALLE et al. 2010)(DALLE et al. 2010)(DALLE et al. 
2010) Filamentation plays an important role in the process of invasion since null 
mutants of efg1 (PARK et al. 2005)  and rim101 (NOBILE et al. 2008b) lack the capability 
of invading the host cell. 
 
 
 
 
 
Figure 6. Mechanisms of fungal invasion into the host tissue.  Adhesion is followed by 
either induced endocytosis or active penetration. Modified from  (ZHU and FILLER 2010) 
 
One of the proteins that plays a role in attachment, Als3, is also important during 
invasion as it can induce endocytosis by binding to E-cadherin, a glycoprotein on the 
epithelial surface  (PHAN et al. 2007).   Members of the Sap family and Plb1 have been 
shown to be important for the invasion of the host surface through penetration.   All of 
these proteins will be discussed in detail later. 
 
1.5.4 Phenotypic switching 
Apart from the yeast-hyphae transitions, the other most extensively studied switching is 
white-opaque phenotypic switching.  It was discovered that this phenotypic switching 
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occurred at a high frequency (10-2) and white and opaque forms could be distinguished 
by cellular and colony morphologies, gene expression profiles and mating competence 
(SLUTSKY et al. 1987).  The protein Wor1 was established as a master regulator of the 
opaque phase (HUANG et al. 2006) while Efg1 was main promoter of white phase 
(ZORDAN et al. 2007).  It was also observed that expression of Sap1and Sap3 was 
specific for opaque cells while Sap2 was specific for white cells  (MORROW et al. 1993).  
It has been observed that strains isolated from vaginitis and systemically infected 
patients show high frequency of switching.  The ability to switch reversibly between 
these two cell types is important for the pathogenicity of C. albicans.  Together, changes 
in the host environment and the virulence traits described above allow for the invasion 
and pathogenesis of C. albicans.  
 
1.6   Known Virulence factors 
The capability of Candida to switch from commensal to pathogen requires several 
virulence traits.  Some of these include adhesion, dimorphic transition, antigenic 
variability, phenotypic switching, immunomodulation of host defense mechanisms, and 
the ability to sequester required nutrients from the host environment to survive and 
proliferate (Figure 3).  Numerous proteins that contribute to these functions and are 
referred to as virulence factors or determinants have been identified in the last few 
decades.  Most of these factors work in a complex network regulating the minute shifts 
in the intracellular and intercellular environment of the pathogen.  Some of these factors 
can be broadly divided into specific groups while many have unique function. 
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1.6.1 Structural and Secreted Proteins 
As mentioned above, the cell wall plays an important role in host recognition, 
attachment and invasion.  There are many different Cell Wall Proteins (CWPs) that play 
crucial roles in pathogenesis.  Most important, are the Adhesins including the Als family, 
Hwp1 (TSUCHIMORI et al. 2000) and Int1 (GALE et al. 1996).  CWPs have become an 
important class of proteins to study because the absence of cell wall in the mammalian 
cells makes the fungal-specific protein components a good target for development of 
antifungal drugs.  Apart from these, proteins like Mnt1 (BUURMAN et al. 1998) and Big1 
(UMEYAMA et al. 2006) are not present on the cell wall but are nevertheless responsible 
for maintaining cell wall integrity and their loss makes the pathogen avirulent.  There are 
also some secretory proteins like Saps and phospholipase, which are hydrolytic and 
play an important role in host tissue invasion.  These are all discussed in more detail 
below. 
 
Als family   
 The Agglutinin like sequence (Als) family consists of 9 genes which encode a shared 
three domain protein structure of which the 5’ domain is the most conserved, while the 
3’ domain is highly variable.  The central domain is comprised of variable numbers of 
tandemly repeated copies of 108bp motifs (Hoyer 2001).  In C. albicans, the ALS 
proteins are Glycophosphatidylinositol  (GPI) anchored and are linked to β 1-6 glucan 
(Kapteyn et al. 2000).  Most of the Als proteins act as adhesins under different 
conditions and some of them may have overlapping functions. For example, it is known 
that Als2 and Als4 have compensatory functions (ZHAO et al. 2005) while Als1 and Als3 
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are redundant for biofilm formation (NOBILE et al. 2008a).  Through expression in S. 
cerevisiae, Als5 was shown to cause adhesion to human epithelial, endothelial and 
extracellular matrix along with endothelial invasiveness by endocytosis (GAUR and 
KLOTZ 1997; GAUR et al. 1999).  
 
Hwp1 
Hyphal cell wall protein (Hwp1), as its name suggests, is only expressed in the hyphal 
cells.  The protein is mannosylated and attached to β1-6 glucan through a remnant of 
GPI anchor.  Hwp1 is responsible for the covalent attachment of germ tubes to epithelial 
cells, and this attachment is mediated by transglutaminases exposed on the host cell 
surface (STAAB et al. 1999).  It has also been demonstrated that HWP1 null mutants 
leads to reduced mortality in mice, less germination in infected mice kidneys and 
reduced endothelial damage, confirming its role in pathogenesis (TSUCHIMORI et al. 
2000). 
 
Sap family 
The Secreted Aspartyl protease (Sap) family of proteins consists of 10 members and is 
the second largest family apart from ALS that has been well characterized.  Saps are 
hydrolytic enzymes that are responsible for invasion of epithelial cells, which eventually 
leads to tissue damage.  Different Saps function in different pH environments.  Sap1-3 
function at pH 3-5, while Sap 4-6 function at pH 5-7 (CHAFFIN 2008).  This further shows 
that depending on niche pH, sap activation can be regulated.  For example, Sap1 and 
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Sap2 are important for causing infection through vaginal epithelium (SCHALLER et al. 
2003). 
 
Int1 
INT1 is an integrin like protein that is required for virulence in a murine systemic model 
of infection (GALE et al. 1996).  Strains deleted in INT1 are less virulent, show reduced 
adherence to epithelial cells and have defective filamentous growth on solid medium 
(GALE et al. 1998).  This indicates that INT1 plays an important role in adherence and 
filamentation.   
 
 Plb1 
Plb1 is an extracellular phospholipase B1 which functions as a lipolytic enzyme.  The 
gene is not required for host surface adherence but is important for host cell penetration 
(LEIDICH et al. 1998).  The gene is also essential for wild type virulence in murine 
systemic model of infection. 
 
1.6.2 Transcription factors in virulence 
Transcription factors play an important role in activating or repressing gene functions in 
response to environmental or intracellular cues.  They play a major role in pathogen 
response to host interaction by regulating the genes that either plays a role in causing 
infection or mounting an evasive response to host immune effectors.  They might also 
help the pathogen in surviving the host environment by assimilating the available 
nutrients from the surroundings.  The effect of transcription factors can be pleiotropic, so 
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only key transcription factors that have a clear role in pathogenesis are described here. 
These are Efg1 and Cph1, Tup1 and Stp1 and Stp2.  The first three are involved in 
hyphal induction (Figure 7), while Stp1 and Stp2 are important for nutrient assimilation. 
 
 
 
Figure 7. Variety of environmental cues can induce C. albicans hyphal formation 
through multiple pathways (SÁNCHEZ-MARTÍNEZ and PÉREZ-MARTÍN 2001) 
 
Efg1 and Cph1  
Filamentation in C. albicans is regulated by several pathways which converge and 
regulate known virulence genes (LANE et al. 2001). Efg1 stands for Enhanced 
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Filamentous Growth, while Cph1 represents Candida Pseudohyphal regulator.  As their 
names suggest Efg1 and Cph1 are both important for the filamentous growth of C. 
albicans.  Efg1 and Cph1 are transcription factors, which are responsible for regulating 
the expression of SAP5 and SAP6.  The pathway also controls the expression of the 
HWP1 gene, which is important for adhesion.  It was also shown that efg1/efg1 
cph1/cph1 double mutants are defective in filamentation and do not form pseudohyphae 
or hyphae in response to many stimuli including serum and macrophages (LO et al. 
1997).  Single mutants were also unable to induce hyphal formation, but a cph1/cph1 
mutation alone was not enough to make the strain avirulent in the C. elegans model, 
while an efg1/efg1 mutation was (PUKKILA-WORLEY et al.).  In the mouse model of 
candidemia, caused by translocation of C. albicans from the GI tract, the double mutant 
causes significantly less mortality compared to the wild type (KOH et al. 2008).  The 
effect is much more pronounced when both of the genes were deleted.  
We also know that Efg1 plays a major role in phenotypic switching, another important 
aspect of fungal infection.  Efg1 is enriched in white phase of cells and is responsible for 
promoting the white phase by repressing WOR1 which is a regulator of opaque phase. 
In turn another protein, Czf1, under the control of WOR1 can repress EFG1 and induce 
transition to opaque phase.  So Efg1 not only controls genes important for filamentation, 
but also genes responsible for phenotypic switching in C. albicans.  Thus it is 
responsible for controlling multiple aspects of fungal pathogenesis. 
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Tup1 
Deoxy Thymidine monophosphate UPtake 1 (Tup1)  is a transcriptional repressor of 
filamentation, as a tup1 mutants grow exclusively as filaments in all common (YPD) and 
specialized media (Spider, Lee’s medium) tested (BRAUN and JOHNSON 1997).  Tup1 
regulates the expression of HWP1 and other cell wall proteins (BRAUN et al. 2000). Tup1 
also plays a role in phenotypic switching, as TUP1 transcripts are 4 fold higher in the 
white phase cells compared to opaque phase cells (ZHAO et al. 2002). 
 
Stp1 and Stp2 
Stp1 and Stp2 are transcription factors are responsible for placing the virulence factors 
associated with nutrient acquisition under amino acid control (MARTÍNEZ and LJUNGDAHL 
2005) .  They show a divergent role in their ability to express genes required to 
assimilate the nitrogen source.  The transcription factors are activated by induction 
through an amino acid sensor present in the plasma membrane.  The activated form of 
Stp1 is then responsible for expressing genes that degrade the extracellular proteins 
through the expression of Sap2 and also helps in the uptake of peptides by expressing 
OPT1, a oligopeptide transporter.  High concentrations of amino acids are known to 
prevent production of Saps (HUBE et al. 1994).  Thus, amino acid induced processing of 
Stp1 is an important regulatory step that allows for the expression of Sap2.  Stp2 is 
responsible for the uptake of amino acids through the activation of amino acid 
permeases like Gap1, Gap2 and Can1. 
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1.6.3 Signaling Pathways 
Multiple signaling pathways are involved in different aspects of fungal pathogenesis.  
Some of these pathways cross-communicate, while others converge to give the same 
end results.  Four main pathways have been identified to be important for fungal 
pathogenesis.  One of these is the Efg1 pathway, which is under the control of cAMP-
PKA, whose activation leads to hyphal development (BOCKMÜHL and ERNST 2001).  The 
other parallel pathway is the Cek 1 MAP kinase pathway, which activates the 
transcription factor Cph1, which is important for hyphal development (CSANK et al. 1998) 
(Figure 6).  The other two pathways of importance are the Mkc1 MAPK pathway and 
HOG pathway. 
 
Mkc1 MAPK pathway 
The Mkc1 pathway in C. albicans is important for maintaining cell wall integrity 
(NAVARRO-GARCÍA et al. 1995).  Cell wall plays a very important role in adhesion to host 
cells (CHAFFIN et al. 1998).  Glucan synthesis is also regulated by this pathway.  mkc1 
mutants are sensitive to cell wall degrading enzymes and antifungals like Caspofungin, 
and are less virulent in a murine systemic model (DIEZ-OREJAS et al. 1997).  Null 
mutants are also defective in producing biofilms and show reduced filamentation 
(KUMAMOTO 2005).  The pathway also affects the immune response as it influences the 
exposure of glucan, which normally occurs in bud scars.  This is important as the 
mammalian receptor Dectin-1 was shown to interact with the pathogen through the 
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exposed glucan layer (BROWN and GORDON 2001) and generate a receptor mediated 
response (BROWN et al. 2003). 
 
Hog1 pathway 
The Hog1 pathway is also important for the biogenesis of the C. albicans cell wall.  This 
pathway is important for controlling responses against osmotic and oxidative stress.  
The null mutant of hog1 shows reduced virulence in systemically infected mice 
(ALONSO-MONGE et al. 1999). The other components of the pathway include Pbs2 
(MAPKK) and Ssk2 (MAPKKK) (CHEETHAM et al. 2007). 
 
1.6.4 Histone Modifiers 
Cellular genes are often controlled at the epigenetic levels by histone modifiers like 
Histone Acetyltransferases (HATs) and Histone Deacetylases (HDACs).  These 
modifiers can also play a crucial role in fungal pathogenesis.  Through the action of 
these modifiers, a number of genes can either be activated or repressed, which can 
affect their virulence of the organism.  One example of such modifier is Rtt109, which is 
a HAT protein and is required for C. albicans pathogenesis.  Rtt109 is responsible for 
acetylation of Histone 3 (H3K56), and is important for resistance against genotoxic 
agents that can cause DNA damage.  During the process of infection, as a host immune 
response, C. albicans cells are engulfed into phagocytes and encounter high levels of 
reactive oxygen species (ROS).  These ROS have the ability to cause DNA damage, 
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and also affect cell proteins and lipids.  Rtt109 null mutants are also significantly 
attenuated in the murine systemic model (LOPES DA ROSA et al. 2010).  Thus Rtt109 is 
important for pathogen’s evasion of the host immune response. 
On the other hand, HDACs are equally important.  As we know white-opaque switching 
affects antigenicity and other virulent traits, so any impact on switching will also affect 
virulence of the pathogen.  For example inhibitors against the HDAC HDA1, negatively 
affect the ability of that strain to adhere to human epithelia or serum induced 
filamentation, indicating that HDA1 could play an important role in fungal virulence 
(KLAR et al. 2001).  Hst3 is a Histone H3K56 deacetylase which along with Rtt109 
regulates white –opaque switching (STEVENSON and LIU 2011).  
  
1.6.5 Other virulence factors 
In addition to all the above mentioned specific type of virulence factors and pathways, 
many more determinants are equally important in virulence but might not fall in any of 
the specified categories.  For example, Fas2, a component of fatty acid synthase is 
required for infection in a murine systemic model (ZHAO et al. 1997).  Similarly,  the 
FTR1 gene which encodes an iron permease important for growth in the bloodstream 
(RAMANAN and WANG 2000).   
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1.7 Model HOSTS used to study fungal virulence. 
Despite all the information that has been gained through in vitro assays of filamentation 
and adhesion to inert and biological surfaces (human epithelium), it is imperative to 
eventually test these observations in a whole animal.  In vivo experiments are important 
as they provide the conditions that the pathogen might actually be facing during the 
process of infection. These could be either the set of proteins that are expressed on the 
surface of the pathogen cell in vivo or the number of host immune responses that it has 
to overcome in order to establish itself.  Whole animal models have to be used to 
explore the different aspects of fungal pathogenicity and host immune responses.  The 
study of virulence factors and their specific roles in in vivo infection process requires the 
use of both a host organism and the pathogen.  This gives a better understanding of the 
role of these factors in host pathogen interactions.  It further helps in identifying general 
and specific host defense responses to the pathogen.   
All these model hosts, share some general characteristics.  They have short life cycles, 
are readily available and easy to maintain in the laboratory.  They are genetically 
amenable and their genomes are sequenced.    For most of these model hosts, there 
are genetic and molecular resources (availability of mutants and RNAi libraries) 
available for immediate use.   A number of model hosts are available and have been 
used to identify virulence factors, such as Caenorhabditis elegans, Drosophila 
melanogaster, Galleria mellonella, Danio rerio, and Mus musculus.  Of these C. elegans 
and D. melanogaster are the most widely used as host followed by M. musculus, while 
G. mellonella and D. rerio are more recent additions.  
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Use of invertebrate host models is beneficial as they are experimentally amenable, have 
conserved innate immune mechanisms between invertebrates and mammals, and 
several common virulence factors are involved in fungal pathogenesis (BEUTLER 2004). 
Comparative analysis has shown that a high proportion of human homologues that are 
involved in pathogen recognition, signal transduction and innate immune responses is 
conserved in C. elegans (55%) and D. melanogaster (60%).  
 
1.7.1 Caenorhabditis elegans 
C. elegans are transparent nematodes that are around 1mm in length. They are either 
self-fertilizing hermaphrodites or males.  They are easy to maintain and grow on E. coli 
lawns, which is their food source.  They have a life span of 2-3 weeks and a generation 
time of ~ 4 days at 20oC.  The larvae can be frozen and the thawed organisms are 
viable, allowing for long term storage of the different worm strains (BRENNER 1974).  All 
the above mentioned attributes fulfill several of the main criteria for a useful model 
organism.  Hermaphrodites are normally used for experiments.  The adult 
hermaphrodites consists of 959 cells, and the developmental lineage of each somatic 
cell has been mapped out (SULSTON and HORVITZ 1977).  The C. elegans genome was 
sequenced in 1998 (CONSORTIUM 1998), and a plethora of genetic and molecular tools 
have been developed for this organism.  Some of these include availability of mutants, 
fluorescently labeled transgenic strains, microarrays and RNAi library (HARRIS et al. 
2010).   
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C. elegans has a conserved innate immune system and thus has been used as a model 
host for studying the effects of many pathogenic bacteria like P. aeruginosa (TAN et al. 
1999b), E. faecalis (SIFRI et al. 2002).  Some fungal pathogens have been studied in C. 
elegans including C. neoformans (MYLONAKIS et al. 2002b), Drechmeria coniospora 
(JANSSON 1994) and very recently C. albicans (BREGER et al. 2007).  C. elegans has 6 
different signaling cascades, TGF β like, Insulin receptor like, programmed cell death 
(PCD) and 3 MAP kinase pathways (p38, JNK and ERK) that are preferentially activated 
depending on the type of pathogen encountered.  RNAi knockdown of TIR1 (Toll and IL-
1 receptor domain) protein, a component of the p38 MAP Kinase pathway, reduces the 
expression of neuropeptide like protein, NLP-31, which is necessary for immune 
response against D. coniospora (COUILLAULT et al. 2004).  NLP-31 is a neuropeptide, 
which is a very potent antifungal peptide.  TIR-1 is also responsible for regulating 
release of antimicrobial peptide NLP-29 against S. marcescens infection (COUILLAULT et 
al. 2004). All of these resources make C. elegans a useful model to study fungal 
pathogenesis.   
 
1.7.2 Drosophila melanogaster 
D. melanogaster is a fruit fly that has been developed as a model organism for many 
decades to study many different aspects of development.  Its genome was sequenced 
in 2000 (ADAMS et al. 2000).  Large number of Drosophila mutants and transgenic lines 
are available for use.  Whole genome RNAi lines are also available (GELBART et al. 
1997). D. melanogaster is also an established model organism in which innate immunity 
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to fungal and bacterial pathogens is studied (MYLONAKIS and ABALLAY 2005). Female 
flies are generally used for infection studies as they are larger in size.   
D. melanogaster has no adaptive immune characteristics but the innate immune 
responses involve both cellular and humoral immunity.  Plasmatocytes act as 
phagocytes and engulf pathogens, while innate immune pathways recognize the 
pathogen and induce the expression of antimicrobial compounds.  These humoral 
pathways are well dissected and involve Toll and IMD signaling pathways. Interaction of 
the pathogen with specific pattern recognition receptors (PRR) leads to the activation of 
the Toll pathway which turns on a cascade of proteins that activate NF-κB-like 
transcription factors.  This transcription factor then leads to the upregulation of 
antimicrobial peptide coding genes.  IMD pathways turn on the Rel family transcription 
factor Relish (LECLERC and REICHHART 2004).   Both transcription factors regulate the 
release of antimicrobial peptides to fight the invading pathogenic organisms. Of these, 
the Toll pathway is known to be more important in response to a fungal pathogen 
(LEMAITRE et al. 1996) by releasing the antifungal peptide drosomycin.   
D. melanogaster has also been widely used to study fungal virulence factors of C. 
albicans using Toll receptor deficient flies (ALARCO et al. 2004). Aspects of phagocytosis 
against C. albicans have been studied using the S2 cell RNAi library of D. melanogaster 
(STROSCHEIN-STEVENSON et al. 2006). Thus, D. melanogaster can be used as a powerful 
model to study innate immunity response mechanisms to various microbial pathogens.  
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1.7.3  Mus musculus  
The Mouse, M. musculus is one of the vertebrate model organisms that has been used 
to model multiple aspects of human biology.  The mouse genome was sequenced in 
2002 (WATERSTON et al. 2002) and is approximately same size as in humans, and many 
mouse genes have human homologues.  Apart from many different aspects of human 
development and behavior, mice are also used to study fungal pathogenesis.  Use of in 
vitro assays and invertebrate hosts has led to identification of a plethora of virulence 
factors in the pathogen.  But, eventually all of these have to be proven in a vertebrate 
model to indicate that the genes are also required in vertebrate hosts.  The relevance of 
these studies to human infections has been shown by the fact that, most of the genes 
that have been implicated as virulence determinants in human infection have been 
eventually proven to be important in either the murine oral candidiasis model, where 
colonization of mucosal surface leads to invasion of the underlying tissue, or the murine 
systemic model of infection, where C. albicans cells are present in the blood stream and 
are disseminated throughout the body.  It is difficult to do a large scale screens in mice 
due to the expense and ethical issues concerning the killing of large number of mice.  
Recently, a systematic screen of a C. albicans homozygous deletion library in mice that 
overcomes these problems has been reported (NOBLE et al. 2010). Despite this, mice 
are currently used on a small scale to finally support either the role of virulence factors 
in fungal infection or the efficacy of antifungals in a vertebrate model. 
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1.7.4 Galleria mellonella 
Use of invertebrate model organisms to study fungal pathogenesis has many 
advantages.  But the biggest limitation is that it does not have an adaptive immune 
system and changes occurring in the pathogen due to the temperature of the human 
host (37oC) cannot be studied.   For these reasons the larvae of the wax moth Galleria 
mellonella, have been developed as a new model in the last decade for the study of 
pathogens, as they can mount both cellular and humoral immune response (TOJO et al. 
2000) like Drosophila, and  be infected at 37oC. They possess phagocytic cells called 
haemocytes. These cells can perform the functions similar to phagocytes, by engulfing 
bacterial pathogens and producing ROS via homologous NADPH oxidase (BERGIN et al. 
2005).  These wax moth larvae have been proven for use in studying bacterial 
pathogens like P. aeruginosa (JANDER et al. 2000) and fungal pathogens like C. albicans 
(BRENNAN et al. 2002), C. neoformans (MYLONAKIS et al. 2005) and A. fumigates 
(JACKSON et al. 2009).  Apart from the study of host-pathogen interactions, the larvae 
can also be used for testing antifungal or antibacterial agents (DESBOIS and COOTE 
2011). 
 
1.7.5  Danio rerio 
D. rerio is a zebrafish that are minivertebrates which are ideal for use as model 
organisms for a number of reasons, among which is that the organisms have much 
more similarity to humans than any invertebrate system used.  Zebrafish (Danio rerio) 
very recently had its genome sequenced and gene microarrays and insertional mutants 
are now available for studies.  Gene specific knockdown even though transitory, can be 
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conducted through morpholino oligonucleotides.  Zebrafish embryos are transparent 
and develop ex utero which allows for the real time visualization of developmental 
changes and other aspects under study.  One limitation is that after 3 weeks 
postfertilization, this transparency is disrupted.  To overcome this drawback, White and 
Zon in 2008 developed a transparent strain of zebrafish called Casper that enables 
visualization of the fish interior even in the adult stage (WHITE et al. 2008).   
In the last few years, apart from studying other facets of biology, zebrafish have become 
a minivertebrate host model for not only innate immunity, but also adaptive immune 
responses (T cell and B cells, granulocytes present) to pathogens.  Zebrafish have been 
used to study host-pathogen interactions especially through the use of strains that have 
fluorescent markers placed under tissue-specific promoters and use of fluorescently 
labeled pathogens. Many different bacterial pathogens for example S. typhimurium  
(VAN DER SAR et al. 2003) and S. pyogens (NEELY et al. 2002) have been very well 
studied in this host.  Since then it was recently shown that zebrafish can also be used 
as a model host to study C. albicans infection (CHAO et al. 2010).  The authors observed 
the effect of deletion of two known C. albicans genes, EFG1 and CPH1 on infection of  
zebrafish.  They observed that lack of these genes resulted in delayed filamentation and 
influenced the expression of several virulence genes including ALS3 and HWP1.  
Similar results have been reported for these strains in mouse model studies.  This and 
other results from their work reveal that C. albicans infection can be studied in 
zebrafish.  The Zebrafish Information Network (ZFIN) is now available online which 
contains almost all the known information about zebrafish in regards to genome 
sequence to commercially available strains. 
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All of the model organisms that have been used to study C. albicans infection have their 
advantages and disadvantages; the biggest one so far is that except for in C. elegans, 
in most cases Candida has to be injected into an individual host for infection to occur, 
which makes them undesirable for high throughput in vivo whole animal studies.   
 
1.8 Summary 
Treatment of systemic fungal infections is difficult because of the limited number of 
antimycotic drugs available.  Thus, there is an immediate need for simple and 
innovative systems to assay the contribution of individual genes to fungal pathogenesis. 
Most of the pathogenesis studies are based on the ability of Candida to form hyphae 
and kill the host.  The aim of this work is to develop a Caenorhabditis elegans based 
assay which will not only allow me to study the role of Candida in the yeast form during 
infection, but also help me monitor the entire infection process, not just death.  
 This can further help me in understanding how the disease progresses once the host is 
infected and also how the pathogen is able to stay fit and counteract all environmental 
pressure like host responses and presence of antimicrobials. Thus, I can identify novel 
virulence factors and pathways that are important in fungal pathogenesis which might 
further be used as potential targets for drug development.   I can also study the general 
and specific C. elegans responses against this pathogen in order to identify host 
immune effectors.  Apart from the candidate gene approach, the availability of mutant 
libraries for the pathogen and small molecule libraries for drug testing will provide me 
with great tools to not only identify novel virulence determinants and mechanisms 
responsible for causing infection, but also using a functional approach, to identify 
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inhibitors of Candida adhesion.  Furthermore, I can also study the difference in 
pathogenicity of the progenitor and evolved strains isolated from patients suffering from 
C. albicans infection. 
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Chapter 2 
 
Patho-assay using S. cerevisiae and C. elegans reveals novel roles for 
yeast AP-1, Yap1 and host Dual Oxidase, BLI-3 in fungal 
pathogenesis. 
 
In order to study the process of fungal pathogenesis in the model host C. elegans, I 
chose to use S. cerevisiae as a benchmark.  C. elegans has been used as a model host 
to identify both bacterial and fungal virulence factors.  The assay that was developed for 
understanding fungal pathogenesis relies on the ability of the fungi to undergo hyphal 
transition and uses death as the disease indicator.  In order to study other intermediate 
effects of fungal infection and the entire infection process, not just death as disease 
marker, I wanted to develop a virulence assay which could mimic normal host pathogen 
interaction conditions.    
Once the assay was developed, in order to further prove that I can use this assay to 
identify virulence factors, I decided to identify the role of a transcription factor, Yap1 
(Yeast Activator Protein1).   
Except for figure 3B and 3C, I performed and analyzed all the work in this chapter. I was 
also involved in designing the experiments.  This work was published as JAIN, C., M. 
YUN, S. M. POLITZ and R. P. RAO, 2009 A pathogenesis assay using Saccharomyces 
cerevisiae and Caenorhabditis elegans reveals novel roles for yeast AP-1, Yap1, and 
host dual oxidase BLI-3 in fungal pathogenesis. Eukaryot Cell 8: 1218-1227.  
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2.1  Abstract 
Treatment of systemic fungal infections is difficult because of the limited number of 
antimycotic drugs available.  Thus, there is an immediate need for simple and 
innovative systems to assay the contribution of individual genes to fungal pathogenesis. 
We have developed a patho-assay using Caenorhabditis elegans, an established model 
host and Saccharomyces cerevisiae as the invading fungus.  We have found that yeast 
infects nematodes causing disease and death.  Our data indicate that the host produces 
reactive oxygen species (ROS) in response to fungal infection.  Yeast mutants sod1∆ 
and yap1∆, which cannot withstand ROS, fail to cause disease, except in bli-3 worms 
that carry a mutation in a dual oxidase gene.  Chemical inhibition of the NADPH oxidase 
activity abolishes ROS production in worms exposed to yeast.  This patho-assay is 
useful for conducting systematic, whole-genome screens to identify fungal virulence 
factors as alternative targets for drug development and exploration of host responses to 
fungal infections.  
 
2.2  Introduction 
Nosocomial microbial infections are a growing health problem.  Among these, fungal 
infections are especially threatening with an estimated mortality rate of 40% 
(WISPLINGHOFF et al. 2003).  The key reason for this alarming mortality rate is the limited 
range of antifungal agents.  Identification of new drug targets requires high throughput 
infection assays that are complicated by the very fact that they involve two organisms: a 
host and a pathogen.   
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We have taken a reductionist approach to studying host-pathogen interactions and have 
developed a Saccharomyces cerevisiae-based assay to understand the genetic and 
molecular mechanisms of fungal pathogenesis.  Using Caenorhabditis elegans as a 
model host, we have found that S. cerevisiae infects the worm, producing visible 
disease phenotypes.  The two organisms used in our study are specifically suited for 
host-pathogen infection studies because both genomic sequences have been 
completely determined and mutants are readily available.  A complete genome 
knockout collection is available in S. cerevisiae, a resource that does not exist for any 
fungal pathogen.  Likewise an RNAi mediated knockdown genomic library is available in 
C. elegans.  These unique tools are key in the context of a genetic screen and allow us 
to systematically scan the entire genomes to identify fungal virulence factors and 
modulators of host immunity that combat a fungal pathogen.   
The budding yeast S. cerevisiae has recently been described as an emerging pathogen 
and has been isolated from human patients (MCCUSKER 2006; MCCUSKER et al. 1994).  
It is routinely used as a model for pathogenic fungi because a large proportion of its 
genes are conserved in pathogenic fungi (for review see (LIU 2001)).  Homologs of 
genes and pathways identified in S. cerevisiae have been shown to be important in 
bona fide pathogens. It has also been used for the identification of gene products 
important for fungal survival in the mammalian host environment (GOLDSTEIN and 
MCCUSKER 2001; WHEELER et al. 2003).  For example the SSD1 allele type affects 
pathogenicity of yeasts, indicating that allelic variation at the SSD1 locus may be 
important for survival under various conditions (WHEELER et al. 2003).  This has allowed 
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investigators to use reverse genetic approaches to study contributions of genes whose 
importance has been established in S. cerevisiae. 
Caenorhabditis elegans has emerged as a valuable model host in which to study 
pathogenesis and innate immunity [for review, see (22)].  Microbial genes essential for 
virulence in mammalian models have been shown to be required for pathogenicity in 
nematodes (SIFRI et al. 2005).  These studies have primarily explored bacterial species 
and have tested only a few fungi, such as Cryptococcus neoformans and Candida 
albicans, to explore virulence strategies.  These studies focus on a killing assay using 
C. elegans and have identified several virulence factors with homologs in S. cerevisiae 
(APIDIANAKIS et al. 2004; MYLONAKIS et al. 2002a) suggesting that genes and pathways 
we identify in S. cerevisiae are likely to be found in pathogens.  Moreover other 
pathogenic fungi tested are limited in the repertoire of laboratory tools available for their 
study, making them recalcitrant to genetic manipulation and inappropriate for whole 
genome high throughput approaches to studying fungal virulence.  Recently, Breger, et 
al. described the application of a C. elegans-based infection assay as a tool to screen a 
chemical library for candidate antifungal compounds (BREGER et al. 2007).  Our 
investigation complements these studies in two significant ways.  First, it allows us to 
identify genes that exacerbate as well as attenuate the pathogenic process because we 
use an intermediate disease phenotype, while most other studies have used death as 
an endpoint phenotype.  This aspect, taken together with the fact that S. cerevisiae 
share significant genetic identity with pathogenic fungi, suggests that our study will yield 
a basic understanding of fungal pathogenesis.  Second, it allows us to conduct a 
systematic, unbiased, whole genome screen, which is currently not available in 
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pathogenic fungi. Furthermore, genes and pathways identified may be targeted for 
antimycotic drug development. 
Facets of innate immunity are evolutionarily conserved from nematodes to mammals.  
For example, a common defense strategy of mammals (phagocytes), (CROSS and 
SEGAL 2004), plants (APEL and HIRT 2004), and insects (HA et al. 2005a), is to produce 
Reactive Oxygen Species (ROS), which directly damage pathogens.  In human 
phagocytes, a NADPH-oxidase enzyme complex produces ROS in host defense 
(GAUSS et al. 2007a; QUINN and GAUSS 2004).  In Drosophila melanogaster, ROS are 
generated in the intestine by a NADPH-oxidase to combat ingested bacteria (HA et al. 
2005a).  Loss of NADPH-oxidase activity makes the fly susceptible to the bacterial 
infection (HA et al. 2005a; HA et al. 2005b).  Likewise C. elegans has also been shown 
to produce ROS such as superoxide and/or hydrogen peroxide when it ingests bacterial 
pathogens (CHAVEZ et al. 2007).  In each case, pathogen death can be abrogated by the 
addition of enzymes such as catalase that break down ROS (BOLM et al. 2004; JANSEN 
et al. 2002; MOY et al. 2004) suggesting that ROS productions plays a key role in a 
variety of pathogenic interactions. 
We have found that S. cerevisiae can cause infection and death in C. elegans.  Our 
data indicate that the nematode host produces ROS in response to fungal infection.  We 
demonstrate that mutant yeast carrying deletions of genes that mediate oxidative stress 
responses fail to induce the Dar disease phenotype except in mutant worms with an 
altered dual oxidase gene, suggesting that the generation of ROS is a part of the 
defense strategy for the host and the neutralization of ROS is needed for persistent 
fungal infection.   
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2.3  Materials and Methods 
Strains, Media and Growth Conditions 
Strains used for the study, for both S. cerevisiae and C. elegans are listed in Table 1. 
Deletions in the yeast-deletion set strains were confirmed by PCR or recreated using a 
PCR mediated gene disruption cassette (WACH et al. 1994).  
Table 1.   Strains used in this study 
Strains Description Source 
S. cerevisiae 
BY4741 MATa;his3∆1;leu2∆0;met15∆0;ura3∆0 IDL* 
Pdc1::mcherry PDC1::mcherry in BY4741 G. Fink, MIT 
yap1∆ yap1∆ in BY4741 IDL 
yap2∆ yap2∆ in BY4741 IDL 
yap4∆ yap4∆ in BY4741 IDL 
sod1∆ sod1∆ in BY4741 IDL 
pdr1∆ pdr1∆ in BY4741 IDL 
pdr15∆ pdr15∆ in BY4741 IDL 
C. elegans 
N2   Bristol Wild type CGC† 
bli-3(e767)I Dual oxidase CGC 
jnk-1(gk7)IV MAPK of JUN MAP kinase pathway CGC 
mek-2(n1989)I MAPKK of ERK MAP kinase pathway CGC 
IDL* – Invitrogen Deletion Library 
CGC†– Caenorhabditis Genetics Center 
  
39 
 
The C. elegans wild-type strain was var. Bristol, strain N2.  Mutant and wild type C. 
elegans strains were obtained from the Caenorhabditis Genetics Center (CGC, 
Minnesota).  C. elegans stocks used for the study were grown on Nematode Growth 
agar medium (NGM) on E. coli OP50 and maintained as described previously (BRENNER 
1974).  E. coli OP50 was grown overnight in Luria Broth at 37oC.  Yeast growth media 
were prepared as described by Sherman et al. (SHERMAN et al. 1986) and strains were 
grown overnight at 30oC. 
 
Egg Preparation 
Worms were grown for 4-5 days on NGM agar containing E. coli OP50 at 20oC.  Eggs 
and worms were washed off four plates with M9 buffer (BRENNER 1974) and centrifuged 
at 900 xg for 2 min.  The pellet was resuspended and washed twice with M9.  This was 
then resuspended in a 1:4 dilution of commercial bleach (5.25%) containing 0.25 M 
Sodium Hydroxide solution, mixed gently by inversion for 3 minutes, and centrifuged for 
2 min at 2000 xg.  The pellet was washed and centrifuged twice with M9 buffer at 2000 
xg for 2 min each and then finally resuspended in M9 buffer.  The egg suspension was 
diluted or concentrated with M9 as required to obtain approximately 5-6 eggs/µl.   
 
Pathogenesis Assay 
E. coli and yeast strains were grown overnight at 37oC and 30oC respectively.  Culture 
aliquots were centrifuged at full speed in a micro-centrifuge, washed twice in sterile 
40 
 
water and finally resuspended to a final concentration of 200mg/ml and 20mg/ml 
respectively.  A 3:1 ratio of E. coli: yeast by weight (an estimated 30:1 ratio by number 
of organisms) mixture was prepared.  A mixture of 10 µl of 50 mg/ml streptomycin 
sulfate stock and 10 µl of E. coli: yeast mix (2.5 µl:7.5 µl) was spotted on each NGM 
plates and 5 µl of C. elegans egg suspension was transferred to each plate.  Plates 
were observed for 4-5 days unless specified otherwise. ANOVA was used to check the 
statistical significance of the differences observed between mutants and wild type yeast 
strains. 
 
Test of Koch’s postulates and measurement of colony-forming units 
Twenty worms each from S. cerevisiae test-plates and E. coli control-plates were picked 
and washed four times with sterile water.  Worms were then crushed using a freeze 
fracture technique in individual microfuge tubes and resuspended in 100 µl of sterile 
water.  Appropriate dilutions of the mixture were transferred to YPD plates and 
incubated overnight.  Colonies were counted to estimate colony-forming units (CFUs).  
Resulting colonies were replica plated to selective media to test for auxotrophic 
markers.  Two of these colonies were retested using the patho-assay described above. 
 
Microscopy of C. elegans 
A 2 % agarose pad containing 0.01 M sodium azide, as anesthetic was prepared on a 
slide.  A 3 µl drop of M9 buffer was added to the pad.  Worms were picked and 
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transferred to the drop on the slide.  Mounted worms were then covered with a cover 
slip and observed at 40 X and 20 X magnifications using an Axiovision Zeiss 
Microscope under DIC (Nomarski) and epifluorescent optics.  An ApoTome attachment 
was used to enhance fluorescence images.   
 
Amplex Red Hydrogen Peroxide Assay 
NGM plates were spotted with 20 µl of 1:1 (v:v) mixture of streptomycin (50 mg/ml) and 
overnight yeast culture.  These plates were then kept overnight at 30 oC.  Approximately 
L3-L4 stage worms were washed off stock plates with M9 and then transferred to these 
plates and kept at 20 oC for 10 hr. Amplex Red Assay Kit (Molecular Probes) was used 
to detect hydrogen peroxide.  Post incubation the worms were washed four times with 
1ml of reaction buffer and resuspended to a final volume of 100 worms/ 50 µl.  50 µl of 
this suspension was added to the wells of a 96 well polystyrene plate.  
Diphenyleneiodonium (DPI) was added to some samples to make a final concentration 
of 100 µM and allowed to stand for 10 min.  Then 50 µl of Amplex Red reaction buffer 
was added to each well and color change was observed over 3-5 hours. 
 
C. elegans survival analysis  
For survival analysis, test plates and C. elegans eggs were prepared as described in 
the Pathogenesis Assay methods section.  Each plate was started with 30 ± 5 eggs; 
each experiment included three yeast and three E. coli plates per strain.  Beginning on 
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the second day after plating eggs, the number of dead and live worms on each plate 
was recorded daily.  Live worms were transferred to new plates as necessary to avoid 
confusing the original worms with their offspring.  All plates were of the same 
composition as the original test plates.   
SigmaStat 3.5 (Systat Software, Inc.) was used to analyze the survival curve data.  
Significance, defined as p<0.05, was assessed using the Gehan-Breslow test.  In our 
experiments, worms that left the plates in the first several days were “censored”, i.e., 
removed from the counts of subsequent days.  The Gehan-Breslow test assumes that 
the data from early survival times are more accurate than later times and weights the 
data accordingly.  The number of censored worms was taken as the total number of 
worms (dead plus live worms) on that day minus total worms on the previous day.  All of 
the data were collected from two independent experiments. 
 
2.4  Results 
Development of an assay for fungal pathogenesis 
Study of host-pathogen relationships would be greatly simplified by the use of two well 
characterized model systems with readily available mutants.  This would allow 
simultaneous study of the genetics of both host and pathogen.  To this end, we 
developed a patho-assay using C. elegans as the model host and S. cerevisiae as the 
invading fungus.  This system will allow us to use systematic whole genome 
approaches to study fungal pathogenesis as well as host responses to fungal infections. 
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In order to study the interaction of S. cerevisiae with C. elegans, the organisms were co-
cultured on NGM plates.  L3 -L4 stage larval or adult hermaphrodites that were offered 
only S. cerevisiae as food successfully laid eggs but their progeny arrested at an early 
(L1-L2 larval) stage of development.  One possible explanation for the larval-stage 
growth arrest phenotype is that the yeast cells were too large for young larvae to ingest.  
To test this we co-cultured hermaphrodite worms on lawns of RFP labeled yeast.  
Within a few hours, labeled yeast (or yeast particles) was visible in the intestinal lumen 
of adult and late stage larvae (data not shown) but not in the early-larval stages.  
Therefore in subsequent assays E. coli was added as a nutritional supply along with 
small amounts of S. cerevisiae.  In this way small larvae could overcome the growth 
arrest while being exposed to yeast. 
C. elegans grown on E. coli as control (Figure 1A) and mixed lawns of E. coli, strain 
OP50 and small amounts of S. cerevisiae, strain S288c, (BY4741) exhibited the 
deformed anal region (Dar) phenotype (Figure 1B).  This phenotype was never seen in 
worms grown on E. coli OP50 alone (Fig. 1A).  The Dar phenotype, which has been 
established as a disease symptom of C. elegans infected with bacteria Microbacterium 
nematophilum (GRAVATO-NOBRE et al. 2005; HODGKIN et al. 2000; NICHOLAS and 
HODGKIN 2004) is characterized as a distinctive swelling in the post- anal region.  It has 
been suggested that the anal region of the worm is enlarged in response to infection, as 
worm mutants that do not show this phenotype are much more adversely affected by M. 
nematophilum infection.  This deformity has been genetically characterized as a part of 
a defense reaction of the worm and can be used as a marker for infection (GRAVATO-
NOBRE et al. 2005).  An intermediate phenotype allows us to identify factors that 
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exacerbate (for example Dar visible earlier or death) as well as attenuate the 
pathogenic response.  Late stage larvae or adult worms grown on yeast alone also 
display the Dar response.  In this study we used Dar as a phenotypic marker and 
previously characterized host genes, involved in the Dar response, as genotypic 
markers of the disease condition. 
 
Figure 1. S. cerevisiae causes a deformity in the post anal region (Dar) in C. elegans. 
(A) C. elegans exposed to E. coli as control. (B) Worms exposed to S. cerevisiae show 
the Dar phenotype (arrow).  Scale – 20µm. (C) The Dar phenotype was scored on Day 
4 for nematodes exposed to E. coli, S. cerevisiae (WT) and heat inactivated (HI) wild-
type S. cerevisiae.  The difference between WT and HI is statistically significant 
(p<0.01, ANOVA). 
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Worms were monitored twice daily from the time the eggs were added to the microbial 
cultures up to day four, when the Dar disease was clearly visible.  At day four the Dar 
phenotype was scored for worms exposed to yeast or heat-inactivated yeast and 
compared to worms reared on E. coli (Figure 1C).  These results clearly indicated that 
the Dar phenotype affected worms exposed to yeast and that only metabolically active 
yeast cells were capable of eliciting Dar.  To test whether the Dar phenotype is 
reversible, we transferred the affected worms to plates containing E. coli.  The worms 
were ‘cured’ of the Dar phenotype within two days of transfer.  This supports the notion 
that yeast causes the deformity in the anal region and that worms can recover by 
clearing the yeast when they are no longer exposed to it. 
The nematode’s response to yeast is unlikely to be due to starvation because 
microscopic observation of the patho-assay plates indicated that at the time when the 
Dar phenotype was visible, ample food was present.  Furthermore the inability of heat-
inactivated yeast and mutant yeast (described in later section) to evoke the Dar 
phenotype strongly supports the notion that this manifestation of infection is a response 
to the pathogen rather than a response to starvation.  We also ruled out the possibility 
that the worms are unable to digest the yeast because L3-L4 stage larvae that are 
reared on yeast develop into fertile adults suggesting that they are able to meet their 
nutritional requirements from yeast.  
As a test of Koch’s postulates, we reisolated and cloned microbes from an infected 
worm after extensive washing to remove externally-associated yeast cells (see 
Materials and Methods). Genotypic characterization of the reisolated yeast 
demonstrated that they harbored the same mutant markers as the original yeast strain.  
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Furthermore, yeast cells from two independent colonies isolated from the worm were 
used to re-infect wild type worms.  These worms showed the same extent of Dar 
disease progression observed with the original yeast strain.  These results indicate that 
the etiological agent for the Dar disease was the one that we introduced, not a spurious 
contaminant. 
 
Progressive distension and accumulation of yeast in the intestinal lumen.  
To visualize yeast present in the intestine and clearly differentiate them from yeast 
sticking to the outside of the worm, we used a fluorescent-tagged housekeeping protein 
to follow progression of disease and specifically test the hypothesis that the intestinal 
distension is due to the accumulation of yeast.  We chose an in-frame fusion of the 
yeast protein pyruvate decarboxylase (Pdc1) with the Red Fluorescent Protein (RFP) 
because its RFP fluorescence was clearly visible and maintained over the five-day 
period of our assay.  Moreover, it was indistinguishable from a yeast strain containing 
the native untagged version of PDC1 in all phenotypic tests (personal communication 
Dr. G. Fink, MIT).   
A time course of microscopic evaluation of infection using RFP-labeled yeast revealed 
that by day three, RFP-labeled yeast cells had started to accumulate in the pharynx and 
the intestine (Figure 2A and 2D).  By day four (Figure 2B and 2E) and day five (Figure 
2C and 2F), progressively more yeast had accumulated in the pharynx and intestine, 
causing the lumen to be severely distended compared to uninfected worms in which the 
intestinal lumen is a narrow tube.  Intestinal distension is also observed in M. 
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nematophilum infection, but bacteria accumulate at the anus and in the rectum near the 
Dar tail swelling and do not extend into the intestine (NICHOLAS and HODGKIN 2004).  
This is in contrast to what we observed - four days post exposure, the intestinal lumen 
appeared to be packed with yeast, and the yeast were not observed to accumulate in 
the rectum.  This striking difference may be indicative of the primary route of entry for 
the fungal pathogen, which appears to be oral ingestion.  Distension of the intestinal 
lumen was also visible in DIC (Nomarski) micrographs of infected worms (Figure 1B).   
Consistent with these microscopic observations, numbers of intact yeast cells released 
from infected worms increased during the course of infection.  CFUs were determined 
for yeast recovered from the worm intestine on days 2, 3 and 5.  A 4-fold increase in the 
number of yeast CFUs was observed between day 2 and day 3 and a10-fold increase 
between day 2 and day 5.    
Between days five and seven, a 5–17 % decrease in viability was observed on yeast 
test-plates.  The progeny of some dead worms appeared to have hatched inside the 
animal.  Upon closer inspection on days four and five, we noted a pronounced swelling 
in the vulval region of these worms (Figure 2H and 2I).  It is possible that this swelling 
impeded eggs from being laid and caused them to hatch within the worm resulting in 
matricidal death.  These qualitative assessments suggest that viable S. cerevisiae 
causes visible lesions near two of the three body openings of C. elegans.  
Coincidentally, such body openings are common sites of fungal infection in mammals.  
Having established phenotypic characteristics of the diseased condition in the worm 
host, we wanted to assay the contribution of known molecular markers of bacterial 
disease in our S. cerevisiae – C. elegans based patho-assay.  
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Figure 2. Time course of intestinal distention in C. elegans exposed to S. cerevisiae.  
Worms were exposed to RFP marked, wild type yeast from hatching and photographed 
on day 3 (A and D), day 4 (B and E) and day 5 (C and F).  The experiment was done 3 
times and 60-75 worms were observed over a 3-day period.  A – C shows the anterior 
region of the worm and D – F shows the posterior region of the worm.  Accumulation of 
yeast began in the pharynx region (compare A and D) and proceeded to the posterior.  
S. cerevisiae also induces vulval swelling in the worms. Worms exposed to S. 
cerevisiae (H – I) show abnormal vulval swelling (white circles) as compared to the 
control sample grown on E. coli (G).  Scale:  A – G = 50µm, H – I = 20µm. 
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Figure 3.  An active ERK MAPK pathway is required for the DAR phenotype and 
survival of worms upon yeast infection.  (A)  Worm mutants jnk–1(gk7) of JUN MAPK 
pathway and mek–2(n1989) of ERK MAPK pathway were exposed to wild-type yeast 
and DAR phenotype was scored on Day 4.  The mek-2(n1989) mutants, but not jnk-
1(gk7) showed decreased Dar compared to the wild-type N2 worms.  Differences 
between mek-2(n1989) or jnk-1(gk7) and wild-type are statistically significant compared 
to the wild type. Values for mek-2(n1989) and jnk-1(gk7) are significantly different from 
wild-type values (*p<0.01, **p<0.001, ANOVA).  (B-C) Survival curves for the mek-
2(n1989) and jnk-1(gk7) mutants indicate that mek-2(n1989) mutant worms were more 
susceptible to yeast than wild-type worms (p < 0.001, Gehan-Breslow test).  The jnk-
1(gk7) mutants survived just as long as their wild type counterparts.  (D-G) Worms 
showing Dar accumulated less yeast, at both, the anterior and posterior regions as 
compared to worms without Dar.  Wild-type nematodes were exposed to RFP marked, 
wild type yeast and photographed on Day 5. The experiment was done 3 times and 20-
25 worms were observed in each experiment.  D – E shows the anterior region of the 
worm and F – G the posterior end of the worm.   E and G are the worms with Dar.   
 
Requirements for C. elegans ERK MAPK pathway in yeast infection - a verification 
of molecular markers of host response 
C. elegans response to pathogens involves the MAPK pathways.  An active ERK 
pathway has been shown to be required for the Dar response of worms exposed to M. 
nematophilum (NICHOLAS and HODGKIN 2004) while the jnk-1 gene, encoding a JNK-like 
MAP kinase, is not required.  The JNK pathway has been implicated in immunity in 
other organisms (DONG et al. 2002).  We tested representative loss-of-function mutants 
in the ERK and JNK MAPK pathways for effects on S. cerevisiae pathogenesis in C. 
elegans (Table 1).  The mek-2 gene encodes a MAPKK in the C. elegans ERK pathway 
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(WU et al. 1995).  The loss of function mutant mek-2(n1989) showed a very low 
percentage of tail deformity when exposed to yeast compared to N2 wild-type worms 
(Figure 3A).  However, a loss-of-function mutation in the JNK-like MAP kinase jnk-
1(gk7) exhibited the Dar phenotype in response to S. cerevisiae.  These effects are 
analogous to the Dar response of nematodes with M. nematophilum infections 
suggesting that the ERK MAPK pathway is required for the tail deformities while the 
JNK MAPK pathway is not. 
To study the contribution of these MAPK pathways to the survival of the host worm 
upon exposure to yeast we conducted survival assays.  This assay measured the 
survival of mutant worms as compared to wild-type worms when exposed to S. 
cerevisiae.  Survival of wild-type worms exposed to yeast versus E. coli was also 
monitored.  Worm mutants were grown on E. coli to evaluate their general health.  Our 
data indicated that the mek-2 mutant that was unable to exhibit the Dar response also 
showed enhanced susceptibility to yeast killing compared to wild-type C. elegans on 
yeast (p<0.001, Gehan-Breslow test, Figure 3B).  By contrast, the jnk-1 mutant that 
showed no defect in its Dar phenotype also showed no difference in survival compared 
to wild-type C. elegans on yeast, and in fact appeared to be less susceptible than wild 
type (p=0.055, Gehan-Breslow test, Figure 3C).  Wild-type C. elegans showed a slight 
yet significant reduction in survival on S. cerevisiae compared to E. coli (p < 0.008, 
Gehan-Breslow test).  The direct correlation between survival of the worm mutants and 
the severity of their Dar response (Figure 3A correlated to Figure 3B and 3C) suggests 
that the Dar response might be a protective phenotype.  To address this we observed 
the extent of intestinal distention (or constipation) in worms exhibiting the Dar 
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phenotype as compared to worms that did not show the Dar response.  We used the 
RFP-marked yeast strain for visualization (Table 1).  We found that wild-type worms 
exhibiting the Dar phenotype accumulated less yeast in their intestine thus enhancing 
survival (Figure 3D- 3G).  Together these results suggest that the ERK MAPK pathway 
is important for the Dar response and protecting the worms from S. cerevisiae infection.  
Albeit the exact defensive mechanism is not clearly understood, a similar observation 
was noted for M. nematophilum infection of C. elegans (GRAVATO-NOBRE et al. 2005; 
NICHOLAS and HODGKIN 2004). 
 
Fungal resistance to oxidative stress is required to establish disease.   
In order to use this patho-assay to identify fungal virulence factors, we used a candidate 
gene approach in which yeast gene-specific deletion mutants were tested for their ability 
to induce the Dar phenotype in C. elegans. 
We chose Yap1 and its paralog Yap2 for this study because these genes have been 
shown to be important in host–pathogen interactions of plant and human fungal 
pathogens (ALARCO and RAYMOND 1999b; LEV et al. 2005a; PRUSTY et al. 2004).  It has 
been shown that Yap1 is activated in conidial germ tubes of Cochliobolus 
heterostrophus, a fungal pathogen of maize, at the earliest stage of plant infection 
and persists during infection (LEV et al. 2005a).  Furthermore, overexpression of 
CAP1 (the C. albicans ortholog of YAP1) confers resistance to the popular clinical 
antifungal fluconazole, an azole derivative (ALARCO et al. 1997a).  However, until this 
study no one had demonstrated that Yap1, or its orthologs, are required for 
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pathogenesis. Yap1 has been recognized as a likely candidate for antimycotic drug 
development because it is a fungal-specific transcription factor of the AP-1 family that is 
involved in multidrug resistance (ALARCO and RAYMOND 1999b; LEV et al. 2005a; 
PRUSTY et al. 2004).  It also regulates oxidative stress responses in fungi as the mutants 
show lack in growth in the presence of reactive oxygen species (COLEMAN et al. 1999; 
ZHANG et al. 2000b). Otherwise there are no apparent growth defects in yap1∆ and 
yap2∆ mutants.  Therefore we chose to test yap1∆ and its paralog yap2∆ in our patho-
assay. 
C. elegans exposed to either yap1∆ or yap2∆ mutants failed to exhibit the Dar 
phenotype (Figure 4A).  As a control we showed that a mutant in a related transcription 
factor, Yap4, did exhibit Dar phenotype (Figure 4A).  These results strongly support 
previous observations in bona fide fungal pathogens that Yap1 plays a key role in the 
infection process.  These studies suggest that Yap1 and its paralog, Yap2, may be 
important virulence factors.  
In addition to the regulation of oxidative stress responses, Yap1 plays a role in 
regulating multidrug resistance genes (ALARCO et al. 1997a; ALARCO and RAYMOND 
1999b).  To define which aspect of Yap1 is required to evoke the Dar response we 
tested mutants that were defective in one or the other responses but not both.  The 
specific mutants tested were Superoxide dismutase (sod1∆) and Pleiotropic Drug 
resistance (pdr1∆, pdr15∆) genes using the same patho-assay.  The physiological role 
for Sod1 is to guard cells against oxidative damage by neutralizing reactive oxygen 
species and the mutants show normal growth except when in the presence of reactive 
oxygen species (BERMINGHAM-MCDONOGH et al. 1988; CHANG et al. 1991; LONGO et al. 
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1999).  Pdr1, like Yap1, is a transcription factor, and regulates resistance to a variety of 
drugs while PDR15 encodes an ATP binding cassette (ABC) transporter of the plasma 
membrane implicated in general cellular detoxification (DECOTTIGNIES et al. 1998; HIKKEL 
et al. 2003; WOLFGER et al. 1997; WOLFGER et al. 2001; WOLFGER et al. 2004).  Like 
yap1∆ and yap2∆ mutants, sod1∆ mutants failed to elicit the Dar response while pdr1∆ 
and pdr15∆ mutants were indistinguishable from their wild-type counterparts (Figure 
4B).  
These experiments demonstrate that the fungal-specific transcription factors, Yap1 and 
Yap2, are required to elicit the Dar response.  These proteins mediate oxidative stress 
responses and drug resistance.  Using mutants defective in only one of these two 
pathways made it unlikely that multi-drug resistance is required for virulence; we believe 
that the inability of Yap mutants to tolerate oxidative stress compromises their ability to 
elicit Dar.  Furthermore, these results suggest that fungi must be able to neutralize ROS 
in order to cause disease.  This presents a testable hypothesis that this requirement 
stems from the fact that C. elegans produce ROS when they are infected with S. 
cerevisiae. 
 
Worms produce reactive oxygen species in response to a fungal infection 
ROS have been shown to play an important role in pathogenesis and defense.  Human 
phagocytes are known to produce ROS when fighting infections (BABIOR et al. 1976).  It 
has recently been shown that C. elegans produce ROS when infected with bacteria 
(CHAVEZ et al. 2007; MOY et al. 2004), presumably as a part of their defense 
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mechanisms.  Worms also produce lipofuscin, a marker of oxidative stress, in intestinal 
cells as they age (GERSTBREIN et al. 2005) and lipofuscin is produced earlier in 
development when young worms are infected with a pathogen that elicits ROS 
production (12).  We tested the hypothesis that young worms exposed to yeast produce 
more ROS by measuring relative amounts of ROS produced in worms exposed to yeast 
as compared to worms reared on bacteria.  We used a commercially available 
biochemical assay (Amplex Red peroxidase kit, Molecular Probes) to test ROS 
produced by the worms in response to pathogenic attack (CHAVEZ et al. 2007).   
Hydrogen peroxide produced by the host oxidizes the substrate, Amplex Red to form a 
red product.  Here we show that worms exposed to yeast produced more ROS than the 
control population grown on E. coli (Figure 4C).  Furthermore, we showed that ROS 
production can be chemically compromised using Diphenyleneiodonium sulfate (DPI), a 
specific inhibitor of NADPH-oxidase activity that does not inhibit peroxidase 
(BINDSCHEDLER et al. 2006).  ROS production in phagocytes is catalyzed by an NADPH-
oxidase (BABIOR et al. 1976) and DPI has recently been shown to inhibit production of 
ROS in nematodes in response to pathogenic attack (CHAVEZ et al. 2007).  Worms 
exposed to yeast that are treated with DPI oxidize Amplex Red only as well as 
unexposed worms (Figure 4C) suggesting that DPI mediated inhibition of the NADPH-
oxidase activity, impedes the ability of the worm to produce ROS.  These results directly 
implicate NADPH-oxidase activity in the host response to fungal infection and suggest 
that such an activity might constitute a protective response against yeast infection.  
These observations prompted us to look for C. elegans proteins that contain a domain 
similar to the mammalian NADPH-oxidase domain, gp91phox. 
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Figure 4. Yap1, Yap2 and Sod1 are required for fungal virulence.  The Dar phenotype 
was scored on Day 4 for nematodes exposed to: (A) yap1∆, yap2∆ and yap4∆ mutants, 
(B) sod1∆, pdr1∆ or pdr15∆ mutants and compared to E. coli or the isogenic wild-type 
yeast strains.  Values for yap1∆, yap2∆, yap4∆ or sod1∆ are significantly different from 
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wild-type values (*p<0.01, **p<0.001, ANOVA).  The pdr1∆ and pdr15∆ mutants are not 
significantly different from wild type (p>0.01, ANOVA).   (C) Production of ROS was 
monitored using Amplex Red reagent in wild type andbli-3 (alleles e767 and n529) 
mutant worms exposed to S. cerevisiae in the presence or absence of DPI.  Each 
experiment was performed in duplicate and repeated 3 times.  Worms treated similarly 
with E. coli was used as a control.  
 
Homology searches revealed that an NADPH-oxidase motif is present in the coding 
sequence of the bli-3 (or Blister-3) locus.  In the encoded protein, the gp91phox motif is 
juxtaposed with a peroxidase domain in a single polypeptide, hence it is referred to as a 
Dual oxidase (CeDuox1) (EDENS et al. 2001; LAMBETH et al. 2000; SIMMER et al. 2003).  
Therefore we tested the hypothesis that CeDuox1 is responsible for generating an 
environment of elevated ROS. 
 
Mutant worms that are unable to produce ROS are susceptible to S. cerevisiae. 
Two mutations, bli-3(e767) and bli-3(n529) have been identified in the gene encoding 
CeDuox1 (SIMMER et al. 2003) The mutant phenotypes of these strains recapitulate 
those produced by RNAi of CeDuox1 (EDENS et al. 2001).  Using the Amplex Red assay 
described above we showed that both mutant alleles of bli-3 produced less ROS when 
exposed to yeast (Figure 4C).  We hypothesized that mutant yeast that are sensitive to 
ROS, hence unable to induce Dar in a wild-type nematode host, would be able to do so 
in a bli-3 mutant worm. To address this we tested the bli-3(e767) mutant allele in our 
patho-assay.  The bli-3 gene encodes the dual oxidase (CeDuox1) that we believe is 
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involved in creating an environment of elevated ROS.  Yeast yap1∆ and sod1∆ mutants 
that are unable to evoke the Dar response in wild type worms are competent to induce 
Dar in bli-3 mutant worms (Figure 5). Furthermore, the bli-3 mutant elicits the Dar 
disease earlier, after three days, in contrast to the wild type, which typically shows Dar 
only after four days.  No Dar phenotype was observed when wild-type N2 and bli-3 
mutant were grown on E. coli as control (data not shown). These results strongly 
support the interpretation that worms exposed to yeast generate a burst of ROS via the 
action of the bli-3 gene product CeDuox1 that inhibits the ability of yeast to induce Dar.  
In the absence of this defensive response, even the yap1∆ and sod1∆yeast mutants 
can induce Dar.  
 
Figure 5.  The yeast yap1∆ and sod1∆ mutants are able to cause Dar disease in C. 
elegans bli-3(e767) mutant.  The bli-3(e767) gene encodes a Dual oxidase (CeDuox1), 
which contains a NADPH oxidase motif that has been implicated in ROS production in 
phagocytes.  C. elegans bli-3(e767) mutants were exposed to yap1∆ and sod1∆ 
mutants and the isogenic wild type as control.  Their Dar response was scored on Day 4 
and compared to wild type worms that were exposed to the yeast yap1∆ and sod1∆ 
mutants and wild-type counter parts.  
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We have used genetic and biochemical approaches on both sides of the host-pathogen 
equation in a patho-assay to demonstrate a role for ROS in the host defense against 
fungal pathogenesis.  We have identified Yap1 and its homolog Yap2 as factors, which 
may be used as targets for antifungal drug development.  We have also identified 
CeDuox1 as a modulator of host responses to yeast infections.  Studies such as the 
current one have the potential of conducting unbiased, whole genome screens to 
identify novel fungal virulence factors and will greatly enhance our knowledge of host 
defense mechanisms in response to fungi.  
 
2.5  Discussion 
Our studies have demonstrated that ROS play a central role in mediating host-pathogen 
interactions in our model.  Using our novel patho-assay with S. cerevisiae as a model 
pathogen and C. elegans as the model host we find that yeast can infect worms 
resulting in intestinal distension, a deformity in the post anal region (DAR) and death of 
the host nematode.  In this study we show that ROS play an important role in fungal 
pathogenesis and host defense.  The C. elegans bli-3 gene encodes a dual oxidase 
known to have mammalian homologs capable of producing ROS.  Our results show that 
two bli-3 mutants with point mutations in the peroxidase domain (SIMMER et al. 2003) do 
not produce hydrogen peroxide in the Amplex Red assay.  This may seem surprising, 
because classically, superoxide produced by NADPH oxidase is converted to hydrogen 
peroxide by dismutation, then to antimicrobial oxidants by peroxidase.  According to this 
model, a mutation in the peroxidase domain would not be expected to alter production 
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of the hydrogen peroxide.  However, it has been suggested that the peroxidase domain 
of the dual oxidases catalyzes dismutation as well as production of antimicrobial 
oxidants (LETO and GEISZT 2006) In that case, a mutation in the peroxidase domain 
might well cause a decrease in hydrogen peroxide production.  Alternatively, a mutation 
in the peroxidase domain may alter the topology of the oxidase domain and decrease its 
activity.  Further studies of the dual oxidases will be required to understand the details 
of their catalytic mechanisms.  
 
Figure 6.  Working model for the role of ROS in early events in host defense and fungal 
pathogenesis. 
 
Our working model (Figure 6) is based on the following results.  In C. elegans the Dual 
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elevated ROS in response to the presence of yeast.  Yeast mutants such as yap1∆ and 
sod1∆ that are sensitive to oxidizing environments are unable to evoke the Dar 
response in wild-type worms but are able to induce it in bli-3 mutants.  Based on our 
data we predict a mechanism in which the nematode produces reactive oxygen species 
(ROS) in response to yeast. The Yap1 and Sod1 gene products of the invading fungus 
must neutralize these ROS before it can cause Dar.  CeDuox1 is expressed in the 
cuticle (EDENS et al. 2001) and our data predicts that it should also be active in the 
intestinal lumen of the worms.  In the future, in situ localization of the CeDuox1 can be 
used to further test our hypothesis.  Mammals also express the Nox family oxidases, 
which include the Duox enzymes, in epithelial tissues including the intestine (EL HASSANI 
et al. 2005; KAWAHARA et al. 2004) and evidence is mounting that these enzymes are 
involved in host defense (LETO and GEISZT 2006). 
C. elegans has successfully been used as a model host for several microbial 
pathogens.  Likewise S. cerevisiae has proved its worth as a prototype for fungal 
pathogens.  This is the first study that demonstrates a pathogenic interaction between 
these two powerful genetic model organisms.  The advantages of being able to study 
both the host and pathogen genetically have been noted previously(PERSSON and 
VANCE 2007).  The present study demonstrates how insights from one side of the host-
pathogen interaction can be used to suggest experiments that can inform what is going 
on in the other side of the interaction.   
This is exciting because in principle, such a study can be extended to the whole 
genome using existing methodologies.  S. cerevisiae is the only fungal species with a 
systematic single gene deletion library.  This assay will enable us to conduct a high 
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throughput, unbiased, whole genome screen to identify fungal virulence factors.  
Promising genes and pathways identified may be targeted for antifungal drug 
development.  On the host side, there are plasmid libraries available containing RNAi 
constructs that down-regulate single transcripts in C. elegans.  Our patho-assay will 
allow us to screen such a library and identify host factors that may be different from 
those identified in bacterial interactions. 
Fungal infections are hard to treat because chemicals that are toxic to fungi are also 
often harmful to human patients.  Thus genes that are unique to fungi are potential 
targets for antifungal agents.  It has previously been suggested that Yap1, a fungal 
specific transcription factor, is involved in pathogenesis (ALARCO and RAYMOND 1999b; 
LEV et al. 2005a; PRUSTY et al. 2004), however it has not been shown to be required for 
pathogenesis.  We use this patho-assay to demonstrate that Yap1 and Yap2 are 
required to elicit a potentially protective host response, the Dar phenotype.  This key 
observation, along with the finding that Yap1 is a fungal-specific transcription factor, 
makes it a likely target for broad-spectrum antimycotic drug development.  
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Chapter 3 
The role of reactive oxygen species in the virulence of Candida 
albicans. 
 
We have previously developed a virulence assay with S. cerevisiae to identify potential 
virulence factors.  Despite all the advantages in using S. cerevisiae, especially plethora 
of tools available for its manipulation, it is not a true pathogen.  C. albicans is the main 
cause of fungal infections, though recently due to fluconazole drug resistance observed 
by Candida, other Candida species such as C. dubliniensis and C. glabrata are 
emerging as pathogens.  My work demonstrates that pathogenesis assay I developed 
works for testing virulence of several diverse Candida spp.   
Using the Dar disease phenotype, I was able to identify a potential role of the S. 
cerevisiae gene, Yap1, in fungal virulence.  I also wanted to test whether the Yap1 
homologue in C. albicans, Cap1, is a virulence factor, not only in this invertebrate 
model, but also in our mammalian models.  I found that Cap1 is required for 
pathogenesis in a nematode host as well as in an in vitro macrophage model.  However, 
in the murine model, deletion of cap1 only partially rescued mouse survival.  This 
indicates that though Cap1 is playing a role in pathogenesis, other factors are involved.   
Cap1 is a basic leucine zipper (bZIP) transcription factor and along with Yap1, Yap2, 
Schizosaccharomyces pombe Pap1 and others constitute a subgroup in Yap family of 
transcription activators.  These proteins in the subgroup have a highly conserved 
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cysteine rich domain (CRD) in their C-terminal.  This domain contains 3 cysteine 
residues which have been shown in Yap1 to be important in regulating nuclear 
localization of the protein in response to oxidative stress (KUGE et al. 1997).   Cap1 
along with regulating the oxidative stress response genes like Ca.GLR1, Ca.TRX2, also 
regulates the expression of MDR1, encoding a multidrug efflux pump and a homologue 
of FLR1 (MOGAVERO et al. 2011).  Treatment with the antifungal Caspofungin also 
induces the nuclear localization of Cap1 (KELLY et al. 2009). 
The experiments shown in table 2 and figures 1, 2 and 4 were performed by me and I 
was involved in designing and analysis of the data collected from the experiments. The 
work shown in this chapter will be submitted for publication.  
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3.1  ABSTRACT 
Candida albicans is a major fungal pathogen of humans, causing mucosal infections 
that are difficult to eliminate and systemic infections that are often lethal, primarily due 
to defects in the host’s innate status. Here we demonstrate the utility of Caenorhabditis 
elegans, a model host to study innate immunity, by exploring the role of reactive oxygen 
species (ROS) as a critical innate response against C. albicans infections. Much like a 
human host, the nematode’s innate immune response is activated to produce ROS in 
response to fungal infection. We use the C. albicans cap1∆ mutant, which is susceptible 
to ROS, as a tool to dissect this physiological innate immune response and show that 
cap1∆ mutants fail to cause disease and death, except in bli-3 mutant worms that are 
unable to produce ROS because of a defective NADPH oxidase. We further validate the 
ROS-mediated host defense mechanism in mammalian phagocytes by demonstrating 
that chemical inhibition of the NADPH oxidase in cultured macrophages enables the 
otherwise susceptible cap1∆ mutant to resists ROS-mediated phagolysis. Loss of CAP1 
confers minimal attenuation of virulence in a disseminated mouse model, suggesting 
that CAP1-independent mechanisms contribute to pathogen survival in vivo. Our 
findings underscore a central theme in the process of infection — the intricate balance 
between the virulence strategies employed by C. albicans and the host’s innate immune 
system and validates C. elegans as a simple model host to dissect this balance at the 
molecular level.  
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3.2  INTRODUCTION 
The incidence of invasive fungal infections has escalated in recent years, primarily in 
hospital settings (PFALLER 1996); 90% of these infections are caused by various 
Candida species (FRIDKIN and JARVIS 1996), 50% of which are fatal (GUDLAUGSSON et 
al. 2003). The estimated annual cost of treating nosocomial Candida infections exceeds 
$1 billion per year and has an attributable mortality of about 5000 deaths per year in the 
United States (MILLER et al. 2001; MORGAN et al. 2005; PAPPAS et al. 2003). Candida 
species are the fourth leading cause of bloodstream infections (BSI), with C. albicans 
responsible for about half the cases. C. albicans form robust biofilms on medical 
implants, such as intravenous catheters, prosthetic joints, or artificial heart valves, which 
can seed potentially lethal disseminated infections (RICHARDS et al. 2000; VELASCO et al. 
2000; WISPLINGHOFF et al. 2003). Approximately 75% of women have at least one 
episode of vaginitis caused by Candida in their lifetime (SOBEL 1988) and oropharyngeal 
thrush and esophagitis are common in both infants and in patients with AIDS 
(DAROUICHE 1998). Candida species also cause superficial infections on mucosal 
surfaces in the body, including the mouth, upper gastrointestinal (GI) and uro-gential 
tract. The frequency of these superficial infections combined with the treatment 
challenges posed by disseminated infections make C. albicans an important pathogen 
for further study. 
A variety of in vitro, ex vivo, and in vivo models have been employed to study the 
interaction between the host and this fungal pathogen. Fully in vitro studies of hyphal 
morphogenesis and biofilm formation, among many others, have yielded important 
insights into virulence (FINKEL and MITCHELL 2011; NOBILE and MITCHELL 2005). Ex vivo 
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models, such as co-culturing C. albicans with isolated macrophages, neutrophils, 
epithelial or endothelial cells, and even intact, perfused organs, have demonstrated that 
C. albicans has very complex responses to host cell contact, which can differ 
dramatically between cell types (FRADIN et al. 2005; LORENZ et al. 2004; PARK et al. 
2009; RUBIN-BEJERANO et al. 2003; THEWES et al. 2007; ZAKIKHANY et al. 2007). A 
murine model of disseminated candidiasis has been frequently used to validate the role 
of specific genes on overall virulence. There is a general appreciation that each of these 
models has provided important insights into fungal pathogenesis. Recently, invertebrate 
models have become additional tools to dissect the roles of components of the 
antifungal host defense system, including flies, wax moth larvae (Galleria mellonella), 
and the nematode Caenorhabditis elegans (BRENNAN et al. 2002; CHAMILOS et al. 2006; 
PUKKILA-WORLEY et al. 2009). 
C. elegans has emerged as a useful model to study infectious disease for several 
reasons. First, facets of its innate immune system are conserved in humans (KIM et al. 
2002; MALLO et al. 2002) and the nematode reacts to pathogens in a manner similar to 
mammals, such as activation of specific signal transduction pathways (JAIN et al. 2009; 
KIM et al. 2002; MALLO et al. 2002; PUKKILA-WORLEY et al.). A rich body of literature 
demonstrates that human pathogens, both bacteria and fungi, also infect C. elegans in 
ways that are mechanistically similar to humans. For example the opportunistic human 
pathogens Pseudomonas aeruginosa (DARBY et al. 1999; KIM et al. 2002; MAHAJAN-
MIKLOS et al. 1999; TAN et al. 1999a; TAN et al. 1999b) and Serratia marcescens (KURZ 
et al. 2003; MALLO et al. 2002), produce toxins that are required for pathogenesis in 
disparate eukaryotic hosts. Mutant studies in Salmonella typhimurium, typically thought 
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to have a narrow host range, shows a direct correlation in virulence between humans 
and C. elegans (ABALLAY et al. 2000; LABROUSSE et al. 2000). More recently a 
comparative study in C. elegans using fungal pathogens of the genus Cryptococcus 
(MYLONAKIS et al. 2002b; MYLONAKIS et al. 2004) showed that only the human pathogen 
C. neoformans, but not other related yeasts (C. kurtzingii or C. laurentii), killed the 
nematode. These studies further demonstrated that a virulence factor such as Kin1, first 
identified in nematodes, was also important in mammals (49). More recent whole 
genome analyses of C. elegans infected with C. albicans reveal that the nematode 
induces immune defenses with known antifungal properties (PUKKILA-WORLEY et al.).  
Studies of C. elegans infected with bacterial pathogens reveal that the generation of 
reactive oxygen species (ROS) is an important part of the nematode’s defense 
response (CHAVEZ et al. 2009; JAIN et al. 2009), a hallmark shared with mammalian 
innate immune responses. We previously reported a C. elegans-based assay to study 
several aspects of disease progression, namely Dar (deformity in the anal region), an 
early marker of infection; intestinal distension, resulting from colonization of the 
intestine; swelling in the vulva, representing infection of other epithelial layers; and 
ultimately death of the host worm (JAIN et al. 2009). Developed initially using 
Saccharomyces cerevisiae, here we have adapted the assay for C. albicans and, using 
genetic tools available in both the fungus and nematode, are able to dissect the role of 
ROS in antifungal innate immunity. We employ genetic and pharmacological tools to 
alter the intricate balance between the host and the pathogen and demonstrate that 
ablating either the ability of the worm to produce ROS or C. albicans to detoxify it (via 
mutation of the Cap1 transcription factor) has dramatic effects on the outcome of this 
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infection. Results in the worm were recapitulated in macrophage co-cultures, validating 
this model. Surprisingly, the C. albicans cap1∆ mutant retained virulence in the 
disseminated murine bloodstream model, suggesting that additional layers of regulation 
of antioxidant defense exist in the context of a mammal. This work thus provides an 
avenue to investigate fungal pathogenesis and has allowed us to identify further 
complexity in the pathogenic C. albicans–host interaction. 
 
3.3  MATERIALS AND METHODS 
Strains, media and growth conditions 
The C. albicans strains used are listed in Table 1 and are based on SC5314 and its 
auxotrophic derivative CAI4-F2. C. albicans transformations were performed via 
electroporation (REUSS et al. 2004). Fungal growth medium was prepared as described 
previously (SHERMAN et al. 1986) and strains were grown overnight in yeast extract-
peptone-dextrose (YPD) at 37°C. The C. elegans strains were grown at 20°C on 
nematode growth agar medium (NGM), spotted with Escherichia coli OP50 and 
maintained as described previously (BRENNER 1974). E. coli OP50 was grown overnight 
in Luria broth at 37°C.  
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Table 1. Strains used in this study 
 
Strains Relevant genotype Complete genotype Source 
C. elegans strains 
N2 Bristol Wild type Wild type (BRENNER 1974) 
CB767 bli-3 bli-3(e767)I (BRENNER 1974) 
S. cerevisiae strains 
BY4741 Wild type MATa; his3∆1; leu2∆0; 
met15∆0; ra3∆0 
(BRACHMANN et al. 
1998) 
C. albicans strains 
SC 5314 Wild type Wild type (FONZI and IRWIN 1993) 
Caf 2-1 URA3/ura3∆ URA3/ura3∆::imm434 (FONZI and IRWIN 1993) 
CJD21 cap1∆/∆ cap1∆::hisG/cap1∆::hisG-URA3-hisG ura3∆/ura3∆ 
(ALARCO and RAYMOND 
1999a) 
AGC2 cap1∆/∆ 
cap1∆::hisG/cap1∆::hisG 
ura3∆/ura3∆ 
RPS10/rps1::URA3-CIP10 
This study 
AGC4 cap1∆/∆ 
complement 
cap1∆::hisG/cap1∆::hisG 
ura3∆/ura3∆ 
RPS10/rps1::CAP1-URA3-
CIP10 
This study 
 
efg1∆/∆ efg1∆::hisG/efg1∆::hisG-URA3-hisG ura3∆/ura3∆ (LO et al. 1997) 
 
cph1∆/∆ cph1∆::hisG/cph1∆::hisG-URA3-hisG ura3∆/ura3∆ (LO et al. 1997) 
 
efg1∆/∆ cph1∆/∆ 
efg1∆::hisG/efg1∆::hisG-URA3-
hisG cph1∆::hisG/ cph1∆::hisG 
ura3∆/ura3∆ 
(LO et al. 1997) 
Other Candida strains 
C. albicans Wild type Clinical isolates (WHITE 1997a) 
C. dubliniensis Wild type Clinical isolates (MORAN et al. 1997) 
C. krusei Wild type Clinical isolates A.B. Onderdonk 
C. tropicalis Wild type Clinical isolates A.B. Onderdonk 
C. parapsilosis Wild type Clinical isolates 
(KUHN et al. 2004; 
LAFFEY and BUTLER 
2005)  
C. glabrata Wild type Clinical isolates (MUNDY and CORMACK 2009) 
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Generation of cap1∆ mutant strains 
The existing cap1∆/∆ strain CJD21 (ALARCO and RAYMOND 1999a) expresses URA3 
from the disrupted cap1 locus, a strategy that has been subsequently demonstrated to 
potentially affect virulence through mis-expression of the URA3 marker (LAY et al. 1998; 
SUNDSTROM et al. 2002); this can be overcome through ectopic integration of URA3 at 
the RPS10 locus using plasmid CIp10 (BRAND et al. 2004; MURAD et al. 2000). To 
generate the cap1∆/∆ mutant and complemented strains with URA3 at RPS10, we grew 
CJD21 on YPD for two overnight passages in YPD, then plated to media containing 5-
fluororotic acid (5-FOA) to select for ura3 auxotrophs (BOEKE et al. 1987). PCR 
amplified the CAP1 open reading frame from genomic DNA of strain SC5314, plus 
~1000 bp of 5’ UTR and ~350 bp of 3’ UTR. This fragment was ligated between the 
XhoI and HinDIII sites in CIp10. This plasmid was digested with StuI and used to 
transform the 5-FOA-selected cap1∆/∆ strain. In parallel, the empty CIp10 plasmid was 
digested with StuI and used to transform the same strain. After selection on SD-Ura, 
correct integration at RPS10 was confirmed by PCR to generate cap1∆/∆ strains with 
either URA3 or CAP1–URA3 expressed from the same genomic site as the mutant 
(AGC2) and complemented (AGC4) strains, respectively.  
 
Microscopic analysis of C. elegans 
A 2% agarose pad containing 0.01 M sodium azide as anesthetic was prepared on a 
slide. A 5 µl drop of M9 buffer was added to the pad. Worms exposed to wild-type 
Candida or RFP-labeled Candida were picked and transferred to the drop on the slide. 
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Mounted worms were then covered with a coverslip and observed at 200X and 400X 
magnifications using an Axiovision Zeiss microscope under differential interference 
contrast (Nomarski) and epifluorescence optics. An ApoTome attachment was used to 
enhance the fluorescence images. 
 
Egg preparation 
Three worms each in the L3/L4 stage were transferred to two NGM agar plates 
containing E. coli OP50 and grown at 20°C for 4 days. On the day of the experiment, 
worms were washed off the plates with M9 buffer and centrifuged at 900X g for 2 min. 
The supernatant was removed and the worms were then re-suspended in a bleach 
solution (1:4 dilution of commercial bleach (5.25%) containing 0.25 M sodium 
hydroxide). The worm suspension was mixed gently by inversion for 3 min and 
centrifuged for 2 min at 2000X g. The pellet was washed and centrifuged with M9 buffer 
at 2000X g for 2 min and then finally re-suspended in 500 µl M9 buffer. The egg 
suspension was diluted or concentrated with M9 buffer as required to obtain 
approximately 30–40 eggs/5 µl. 
 
Pathogenesis assay 
E. coli and Candida strains were grown overnight at 37°C. Culture aliquots were 
centrifuged at full speed for 1 min in a table top microcentrifuge and the supernatant 
removed. Pellets were washed twice in sterile deionized water, and re-suspended to a 
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final concentration of 200 mg/ml and 10 mg/ml, respectively. Next, a mixture of 10 µl of 
a 50-mg/ml streptomycin sulfate stock to inhibit E. coli growth, 7 µl of distilled water, 
2.5 µl of E. coli and 0.5 µl of Candida was spotted on to each NGM plate. E. coli spotted 
plates were used as control. Finally, 5 µl of C. elegans egg suspension was transferred 
to each plate. Plates were then kept in a 20°C incubator and were observed for 5 days. 
All the experiments were done in triplicate. Student t-test was used to check the 
statistical significance of the differences observed between wild type and other Candida 
strains. 
 
C. elegans survival analysis 
Survival analysis was done on the CAP1/CAP1, cap1∆/∆ + CAP1, and cap1∆/∆ strains 
and plates were prepared as described under egg preparation and pathogenesis assay. 
Starting on Day 3 following the initial assay, the number of worms alive, dead, and dead 
on the rim was recorded each day. In order to differentiate between the first-generation 
worms and their offspring, worms were transferred every 2 days to new plates that were 
prepared the day before as previously discussed and incubated overnight at 20°C. 
For data analysis, SPSS (IBM, Inc.) was used to generate Kaplan–Meier survival 
curves. In this experiment, each worm that died on the plate was entered as a "1", 
indicating the event of death due to fungal disease took place. Worms that were found 
dead on the rim of the plate were censored and entered as a "0", since death occurred 
for a non-related reason. Significance, as defined as a p value < 0.05, was assessed 
using the Gehan–Breslow test. This test assumes that data from earlier survival times 
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are more accurate than later times and weights these data accordingly. Data were 
combined from three plates and another independent experiment gave the same 
results. 
 
Macrophage growth inhibition assay 
Macrophage cell line RAW 264.7 (ATCC) was used in the assay. The cell line was 
maintained in DMEM supplemented with 10% fetal bovine serum (FBS). The protocol 
was slightly modified from the original (LOPES DA ROSA et al. 2010). Briefly, 
macrophages, on reaching 80–90% confluence, were scraped and brought up in DMEM 
supplemented with 10% FBS, 100 U/ml penicillin or 100 µg/ml streptomycin, then 
2 × 106 macrophage cells were plated on 35 mm2 plates and allowed to adhere for 5 h. 
Candida strains were grown overnight at 37°C and diluted 1:10 and allowed to grow for 
another 5 h. Candida cells were then washed with supplemented DMEM and were 
added to the plates containing macrophages in a ratio 1:15 macrophage and to a final 
volume of 2 ml. Yeast strains were grown in parallel without macrophages under 
identical conditions to calculate percent survival. Plates were incubated overnight at 
37°C and 5% CO2. Cells were then brought up to 24 ml in a tube using 0.05% Triton X-
100 (v/v) in water to osmotically lyse the macrophage cells. Dilutions were prepared and 
plated on YPD plates and grown overnight at 37°C. Colony forming units (CFUs) were 
counted and percent survival was calculated by taking the ratio of CFU from co-culture 
of Candida and macrophage to the CFU obtained for Candida alone. 
Experiments involving diphenyleneiodonium chloride (DPI) were performed as 
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mentioned above but with the addition of 0.05 µM DPI from a 31.8 mM stock solution in 
DMSO. Controls without DPI had the same concentration of DMSO. Statistical analysis 
was done using Student’s t-test. 
 
Mouse virulence assay 
Mouse virulence assays were carried out as described previously (RAMIREZ and LORENZ 
2007). Female, adult (21–25 g) ICR mice (Harlan) were maintained on a normal 
laboratory diet. C. albicans strains were passaged twice in overnight cultures in YPD, 
then diluted into fresh YPD and grown for 3 hours at 30°C. Cell were collected by 
centrifugation, washed with water and re-suspended in PBS, then diluted and counted 
with a haemocytometer. Cells were diluted to 1 × 108 cells/ml in PBS. Mice were 
injected with 100 µl of this suspension via the tail vein, with groups of 10 mice/strain. 
Animals were monitored 2–3 times daily for signs of infection and were euthanized 
when moribund. Survival data were analyzed with Prism5 (Graphpad Software) using 
the log rank test. All animal experiments were conducted in accordance with protocols 
approved by the University of Texas Health Science Center Animal Welfare Committee. 
 
3.4  RESULTS 
Generation of CAP1 homozygous and complemented strains 
The original cap1∆/∆ mutant strain CJD21 was generated by Raymond and colleagues 
(ALARCO and RAYMOND 1999a) using an approach that was subsequently shown to be 
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inappropriate for animal experiments due to the variability of expression of the URA3 
selectable marker. We selected a ura3- derivative of the cap1∆/∆ strain CJD21 on 5-
FOA, then integrated either URA3 or URA3–CAP1 at the RPS10 locus using plasmid 
CIp10, a strategy shown to stably express URA3 during infection (MURAD et al. 2000). 
This generated a cap1∆/∆ mutant strain (AGC2) and a complemented strain (AGC4); 
the mutant strain is phenotypically identical to the original CJD21 during in vitro 
challenge with ROS (data not shown).  
 
In vivo virulence assay for Candida infection  
We previously described a pathogenesis assay where a small quantity of S. cerevisiae, 
a model pathogen, was introduced with the nematode’s standard diet of E. coli OP50. 
The E. coli was attenuated to avoid interactions with the fungal species under 
investigation (JAIN et al. 2009). We uncovered molecular mechanisms of fungal 
virulence and the reciprocal innate immune response of nematodes, which is also 
conserved in mammals (GAUSS et al. 2007b; ZU et al. 1998). Here we have adapted this 
assay to test various fungal pathogens of the Candida genus, including C. albicans, 
C. dubliniensis, C. krusei, C. tropicalis, and C. glabrata. We decreased the 
concentration of Candida in the feeding mixture by 30-fold because of the increased 
pathogenicity of Candida species, and even at this lower fungal burden, several species 
induced Dar in 100% worms, compared with S. cerevisiae, which induced 0% Dar at the 
same concentration of inoculums (Table 2).  
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Table 2: Percentage Dar observed for different clinical isolates 
 
 
 
 
 
 
 
 
 
Disease phenotypes of C. elegans upon C. albicans infection 
Subsequent studies focused on C. albicans because it is the most prevalent infectious 
species in this genus (GUDLAUGSSON et al. 2003) and adequate genomic and molecular 
tools have been developed. To visualize infection, disease progression and death, we 
exposed nematodes to C. albicans and observed them daily over a 6-day period. The 
Dar phenotype was clearly visible in every worm on Day 4 (Fig. 1 and Table 2). Swelling 
in the vulva region was also noted in the worms infected with C. albicans (Fig. 2B).  
 
 
Strains % Dar n = 
C. albicans (SC 5314) 100 114 
C. albicans 100 111 
C. dubliniensis  100 122 
C. glabrata  59.7 ± 1.1 119 
C. parapsilosis  4.9 ± 0.3 133 
C. krusei  100 115 
C. tropicalis  100 134 
 S. cerevisiae (BY4741)  0 76 
(± standard error) 
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Figure 1: C. albicans induces deformed anal region (Dar) in wild-type worms. Worms were 
exposed to E. coli as control (uninfected) and C. albicans (shown are two examples of infected 
worms) and pictures were taken on Day 4 (arrow indicates the Dar region). Scale = 20 µm.  
 
The worm succumbed to the infection following these phenotypic observations. To 
observe colonization of the intestinal lumen, worms were exposed to mCherry-labeled 
C. albicans (mCherry labeled SC5314, gift from Dr. Robert Wheeler, Univ. of Maine). 
Time-series micrographs of worms infected with C. albicans indicated that the intestinal 
lumen was colonized 2 days post-exposure compared with uninfected worms. 
Considerable intestinal distension was observed in infected worms on subsequent days 
(Fig. 2A) compared with the uninfected control population. In general, the disease 
phenotypes were more robust with C. albicans compared with S. cerevisiae, even with 
lower inoculum for infection.  
To further validate our assay we tested known mutants efg1∆ and cph1∆ — previously 
documented virulence factors that regulate hyphal transition of C. albicans (LO et al. 
1997) and have been shown to be important in in vivo infections of mice and nematodes 
(KOH et al. 2008; PUKKILA-WORLEY et al.). The efg1∆ and cph1∆ single mutants showed 
decreased Dar ~10% and ~50%, respectively, compared with the cognate wild type, 
while the efg1∆ cph1∆ double mutant failed to induce any Dar (0% Dar). 
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These results recapitulate the pattern of virulence in mice, where the cph1∆ mutant is 
slightly attenuated, the efg1∆ mutant is significantly attenuated, and the double mutant 
is completely avirulent (LO et al. 1997). Accordingly, our assay is suitable for exploring 
virulence strategies of C. albicans and the reciprocal host defenses that may be 
correlated to aspects of innate immunity that is conserved in mammals (KIM et al. 2002; 
MALLO et al. 2002).  
 
Figure 2: Different phenotypes are observed due to Candida infection. (A) Exposure to C. 
albicans causes intestinal distention in the worms over time (Days 2, 3 and 4). DIC (Nomarski) 
pictures of worms feeding on E. coli was taken as control and the DIC, RF and merged pictures 
of worms infected with C. albicans are shown over 3 days. (B) Vulva swelling is observed (arrow 
points to the vulva region) by Day 4 when worms are exposed to Candida compared with worms 
exposed E. coli as control (uninfected). Scale = 20 µm. 
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CAP1 is required to establish infection in nematodes 
In vitro, Cap1 regulates the response to oxidative stress (ALARCO and RAYMOND 1999a; 
ENJALBERT et al. 2006; WANG et al. 2006; ZHANG et al. 2000a), which is a key 
component of the human innate immune response to fungal infections and is induced in 
the presence of neutrophils (FRADIN et al. 2005). To correlate these studies, performed 
at 30°C and 37°C, respectively, with our in vivo infection, performed at 20°C, we 
compared the ROS sensitivity profiles of cap1∆/∆, CAP1-complemented, and the 
cognate wild-type strain at the following temperatures: 20°C, 30°C and 37°C. Our 
reconstructed cap1∆/∆ mutant failed to grow in the presence of hydrogen peroxide (at a 
final concentration of 2 mM) while the CAP1-complemented strain showed the same 
growth as the wild type at all temperatures tested (data not shown). These results 
indicate that ROS sensitivity of the cap1∆/∆ strain is independent of temperature and 
that all C. albicans strains used in this study show the same phenotype at all 
temperatures used in this study.  
To test whether the mechanism by which Cap1 promotes virulence is related to the 
production of ROS by the host, we compared the Dar response of worms exposed to 
null mutant (cap1∆/∆) and wild-type strain (CAP1/CAP1) as well as a CAP1-
complemented strain (cap1∆/∆ + CAP1), where a single wild-type copy CAP1 is 
replaced at the native locus. The wild-type strain was able to induce Dar in 100% of the 
worms while the cap1∆/∆ homozygous mutant showed a significant reduction in Dar 
induction (Fig. 3A). The CAP1-complemented strain showed an intermediate Dar 
response that is commonly observed for complemented strains because a diploid 
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deletion is complemented with a single copy. This result indicates that Cap1 function is 
required for full virulence in the nematode model. 
 
Figure 3: Cap1 is a virulence factor that is required for counteracting oxidative stress created by 
the host during fungal pathogenesis. The Dar phenotype is observed for both (A) wild type and 
(B) bli-3 mutant worms (which lack the ability to produce ROS) exposed to CAP1/CAP1, 
cap1∆/∆ + CAP1, and cap1∆/∆ strains (* denotes p < 0.001; n denotes the number of worms 
exposed to a particular strain). Experiment was done in triplicate. (C) Survival curves for wild-
type worms when exposed to CAP1/CAP1, cap1∆/∆ + CAP1, and cap1 ∆/∆ with E. coli OP50 
as control (p < 0.01 for CAP1/CAP1 and the cap1∆/ ∆ mutant) show that worms exposed to 
cap1∆/∆ survive longer than worms exposed to wild type, while (D) bli-3 mutant worms exposed 
to Candida strains show no difference in survival between exposure to wild-type CAP1/CAP1 
and the cap1∆/∆ mutant. 
 
The bli-3 gene contains the only NADPH oxidase moiety in C. elegans genome, where it 
is found fused the peroxidase domain (hence called Dual oxidase, or Duox) (EDENS et 
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al. 2001). We and others previously reported that Bli-3 produces ROS in response to 
pathogenic insult (CHAVEZ et al. 2009; JAIN et al. 2009). To test the hypothesis that 
Cap1 is responsible for counteracting this oxidative environment upon C. albicans 
infection, we exposed bli-3 mutant worms to cap1∆/∆, CAP1-complemented, and wild-
type CAP1/CAP1 strains. As shown in Figure 3B, the Dar phenotype of bli-3 mutant 
worms infected with the cap1∆/∆ null mutant is indistinguishable from that of the wild 
type and complemented counterparts, suggesting that Cap1 function is not required for 
infection if the host cannot produce ROS. Thus, Cap1 is dispensable when the ROS 
production part of the host’s defense repertoire has been compromised, as in the bli-3 
mutant.  
 
CAP1 is required to sustain infection and ultimately kill the nematode host 
We and others previously showed that Dar is an early indicator (HODGKIN et al. 2000; 
JAIN et al. 2009) of an eventually lethal infection, which is reduced in worms exposed to 
the cap1∆/∆ null mutant. To test the hypothesis that these mutants are avirulent, we 
measured the life span of worms infected with the cap1∆/∆ null mutant, complemented, 
and wild-type strains relative to uninfected worms. The average lifespan of C. elegans 
infected with wild-type C. albicans (CAP1/CAP1) or a CAP1-complemented strain was 
significantly shorter (median survival is 6 days) than those infected with the cap1∆/∆ 
null mutant (median survival is 13 days) (Fig. 3C). These data indicate Cap1 is required 
for the infection to persist and ultimately kill the hosting worms. To test the hypothesis 
that Cap1 is required to neutralize host ROS we challenged an ROS-deficient bli-3 
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mutant host with the C. albicans cap1∆/∆ mutant. Lifespan plots reveal that the kinetics 
of killing are indistinguishable between the cap1∆/∆ mutant and the wild type or 
complemented strains (Fig. 3D), suggesting that ROS is the primary defense of 
nematodes against C. albicans but that C. albicans requires Cap1 for a lethal infection 
to persist. The lifespan of uninfected bli-3 mutants is the same as their wild-type 
counterparts (Fig. 3), eliminating confounding factors other than ROS production as a 
likely cause of death of infected worms.  
 
Cap1 is responsible for neutralizing ROS produced by phagocytes 
Part of the mammalian host defense against Candida infection is production of ROS 
within phagosomes that have engulfed the fungal pathogen (VAZQUEZ-TORRES and 
BALISH 1997). Wild-type C. albicans can effectively neutralize ROS to survive (ARANA et 
al. 2007; FROHNER et al. 2009; LORENZ et al. 2004; WELLINGTON et al. 2009; WYSONG et 
al. 1998) and eventually cause the macrophages to lyse. To test whether Cap1 
mediates this key innate immune response that allows C. albicans to withstand the 
oxidative environment, we co-cultured macrophages with either wild type or cap1∆/∆ 
strains. Our data indicate that the CFUs of C. albicans recovered from macrophages 
were significantly lower for cap1∆/∆ null mutant compared to the cognate wild type (Fig. 
4); the complemented strain survived macrophage phagocytosis to an extent similar to 
the wild type. 
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Figure 4: Cap1 is required for survival in macrophages. Macrophages were exposed to different 
strains of Candida in a ratio of 1:15 macrophages with and without DPI. Percentage survival 
was calculated by dividing the CFUs obtained for Candida grown with macrophages to Candida 
alone. Data were then normalized to the wild type. Percent survival of cap1∆/∆ mutant is 
significantly less (**p < 0.05) than the wild type and the complemented Cap1 strain.  
 
To further correlate the survival of phagocytized C. albicans with ROS production within 
the phagocytes, we chemically inhibited ROS production in the phagosomes with 
Diphenyleneiodonium chloride (DPI) (HANCOCK and JONES 1987). DPI specifically 
inhibits NADPH oxidase (BABIOR 2004), a homolog of Bli-3 responsible for ROS 
production in macrophages. In the presence of DPI, there was no difference in CFUs 
recovered from macrophages between the three strains, suggesting that 
pharmacological inhibition of the host ROS-production machinery allows cap1∆/∆, 
which is otherwise attenuated, to survive within the phagosome. These results mimic 
our genetic studies in nematodes and suggest that C. albicans relies on Cap1 to 
neutralize the oxidative environment within the phagosome, and that eliminating the 
source of ROS in phagosomes eliminates the need for Cap1. 
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CAP1 has a limited effect during mammalian infection 
The cap1∆/∆ mutant is clearly attenuated in the nematode model and during contact 
with macrophage, and has previously been reported to be hypersensitive to several 
sources of oxidative stress (ALARCO and RAYMOND 1999a). We tested it in the standard 
mouse model of disseminated candidiasis, in which C. albicans is introduced directly 
into the circulatory system via the tail vein. We injected outbred ICR mice with 106 
C. albicans cells and monitored for signs of infection (Fig. 5; see Materials and 
Methods).  
 
Figure 5: Candida virulence is reduced when Cap1 is deleted. Ten mice/strain were injected in 
the tail vein with 106 cells of the respective Candida strain. Survival curves of mice when 
infected with CAP1/CAP1, cap1∆/∆ + CAP1, and cap1∆/∆ strains show that mice infected with 
the cap1∆/∆ mutant were able to survive significantly longer than those injected with the wild 
type (p < 0.01 for CAP1/CAP1 and the cap1∆/∆ mutant). 
 
Mice inoculated with the cap1∆/∆ strain had a statistically significant increase in median 
survival times relative to wild type (from 6.0 to 8.5 days, p = 0.0003). However, the 
CAP1-complemented strain showed roughly the same virulence (median survival 8.0 
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days). Thus, despite the worm and macrophage data, in vitro cap1∆/∆ phenotypes, and 
the general assumption that the oxidative burst is a key part of the anti-fungal innate 
immune response, we show that loss of CAP1 alters virulence only slightly. 
 
3.5  DISCUSSION 
 
Mammalian biology has been effectively modeled using a variety of species that present 
substantial advantages in complexity, genetic tractability, ethical considerations and 
cost. The last decade has seen the acceptance of invertebrates, such as C. elegans, as 
relevant hosts that can contribute to the molecular understanding of microbial 
pathogenesis. The C. elegans model, which has been generally used to study systemic 
pathogens such as Cryptococcus, Pseudomonas and Enterococcus, clearly differs from 
mammalian infection in several respects, including the site of infection (gut vs. 
bloodstream), growth temperature (25–30°C vs. 37°C) and the absence of an adaptive 
immune response. Yet, equally clearly, C. elegans and other invertebrates have 
provided important insights into bacterial and fungal pathogenesis and many mutants 
have been uncovered that attenuate virulence both in the worm gut and in the mouse 
bloodstream (KURZ and EWBANK 2000; MACCALLUM 2012; PRADEL and EWBANK 2004). 
We show here a case in which the worm offers opportunities to dissect the important 
components of the innate immune response to fungal pathogens. More importantly, we 
are able to tease out the differences between mammalian and nematode models using 
the C. albicans cap1∆/∆ strain. 
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We previously demonstrated that the model yeast S. cerevisiae can cause pathology in 
the nematode (JAIN et al. 2009). In this work we show that this assay is far more robust 
when using pathogenic Candida species and that the virulence of these species in the 
worm roughly correlates with virulence in humans. The worm has emerged as a 
valuable model to investigate host responses because aspects of its innate immune 
system are conserved in humans. In addition, our nematode infection assay faithfully 
recapitulates the ROS-mediated innate response observed in humans. 
Generation of ROS has been shown to be an important component of the worm’s 
defense against bacterial infections (CHAVEZ et al. 2009) and we demonstrate that here 
for fungal infections as well. Data presented here indicate that Cap1, a fungal-specific 
transcription factor known to regulate oxidative stress responses (ALARCO and RAYMOND 
1999a; WANG et al. 2006) and drug resistance pumps (ALARCO et al. 1997b), is required 
for virulence of C. albicans in nematodes and cultured macrophages. Specifically, 
strains lacking CAP1 induce the Dar phenotype less frequently and attenuate virulence 
in a worm-killing assay relative to the wild-type strain. This is directly due to the 
increased sensitivity of this mutant to ROS because mutant worms that cannot produce 
ROS due to a mutation in the host oxidase do not show early signs of infection, nor do 
they succumb to an infection with the cap1∆/∆ null mutant. Furthermore when the 
NADPH oxidase is chemically inactivated in cultured macrophages, cap1∆/∆ null 
mutants are able to survive just as well as wild-type Candida. 
Given the data above and the known in vitro functions of CAP1, the results of the 
murine model are surprising, as it is difficult to conclude that loss of CAP1 alters 
virulence. Since some other antioxidant proteins, such as the secreted superoxide 
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dismutase SOD5 and catalase CAT1, are attenuated in this same model (MARTCHENKO 
et al. 2004; NAKAGAWA et al. 2003; WYSONG et al. 1998), it seems clear that anti-oxidant 
defenses are important in vivo. There is a small difference in the mutant and wild-type 
strain, but the difference is not eliminated in the complemented strain. It is possible that 
the reintroduction of a single copy of CAP1 is haploinsufficient in a mouse, though this 
strain fully complements all in vitro phenotypes. A more intriguing possibility is that there 
may be Cap1-independent mechanisms for their induction in the context of the 
mammalian host. Indeed, SOD4 and SOD5 are both more highly expressed in hyphal 
cells, which can be induced in response to several host-associated cues (FROHNER et 
al. 2009; MARTCHENKO et al. 2004). Thus, our C. elegans model may allow analysis of 
critical fungal responses to the innate immune system that could be masked by 
phenotypic redundancy in the context of the intact mammal. 
Genetic tractability is a key advantage of the C. elegans assay, even over other 
invertebrates, and our model is intended to maximize the potential of the nematode. By 
feeding C. albicans to C. elegans we avoid manipulation of individual animals, a time-
consuming aspect of screens in both vertebrate and other invertebrate species such as 
mice, zebrafish, Drosophila or Galleria larvae. Further, our virulence assay can be 
differentiated from other C. elegans-based assays because we include attenuated E. 
coli as the primary nutritional source and spike in C. albicans as the infectious agent. 
This avoids any complicating factors that may come from altered nutritional states, since 
we have found that C. elegans does not feed well on a lawn of fungal cells alone (M.L. 
and R.P.R., unpublished observations). In addition, this system can be easily adapted to 
conduct systematic mutant screens for modulators of the innate immune response using 
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the existing RNAi knockdown collection, available as E. coli strains expressing double-
stranded RNA that is specific to any C. elegans gene and that knock down the gene’s 
protein concentration to a negligible amount. In conclusion, we have shown that this 
model system offers a robust means to probe both innate immunity and fungal 
pathogenesis. 
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Chapter 4 
Mutant screen to identify novel potential virulence factors. 
Prevalence of C. albicans infection in hospital settings has been increasing in the last 
few decades.  In order to understand the repertoire of virulence strategies used by C. 
albicans, we used the C. elegans – C. albicans pathogenesis assay that I have 
described earlier to conduct a mutant screen.  We screened a transposon-mutagenized 
insertion library of ~1200 Candida clones to identify novel factors required for Candida 
infection.  Using the assay, we identified some known and some novel genes that 
showed altered virulence in C. elegans.   Some of these genes are uncharacterized and 
pose future possibilities for investigation.  
The screening of the mutant library was done by 4 undergraduates, under my guidance.  
I was involved in designing and analyzing the data.  I was also responsible for 
troubleshooting any problems that occurred during the screen.   
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4.1  INTRODUCTION 
C. albicans is an opportunistic pathogen that is normally found in the mouth, 
gastrointestinal and uro-genital tract of humans.  Under conditions such as prolonged 
use of broad-spectrum antibiotics or a compromised immune system due to AIDS or 
transplants, this commensal can proliferate and cause infection.  The use of invasive 
devices like catheters and other implants facilitates systemic candida infection (FINKEL 
and MITCHELL 2011; VELASCO et al. 2000).  C. albicans is the fourth leading cause of 
hospital-acquired blood stream infection with a mortality rate of 50% (GUDLAUGSSON et 
al. 2003).  Drug resistance exhibited by Candida exacerbates the problem of treatment, 
and limited availability of different drugs adds to the problem.  Thus, there is a need to 
understand the full repertoire of virulence strategies used by Candida.  Studies are been 
conducted to better understand the triggers that facilitate the commensal to pathogenic 
switch and other processes required for pathogenesis and host adaptation during the 
process of fungal infection (ZHU and FILLER 2010). 
In vivo screens have been developed using both invertebrate and mammalian models to 
study different aspects of fungal pathogenesis.  The mammalian study is a fitness assay 
in which a mouse is injected with a mixed population of barcoded mutants of C. 
albicans.  Usually mutants with a virulence defect have reduced competitive fitness and 
are selectively depleted in the host.  Abundance of C. albicans strains is determined 
with real time PCR and mutants missing when compared to the inoculum are 
considered avirulent (NOBLE et al. 2010).  However, using mice for high throughput 
screening can be cost prohibitive.  Use of invertebrates for screens is not only 
inexpensive but helps in avoiding ethical issues associated with using mammalian 
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systems.  They are also beneficial for screening both the aspects of host-pathogen 
interaction; virulence factors and host immune effectors.  The invertebrates that are 
normally used for such screens are either D. melanogaster or C. elegans.  One such 
screen for host immune effectors that has been reported is the RNAi based D. 
melanogaster S2 cells screen to explore the role of 7,216 genes in phagocytosis of 
Candida (STROSCHEIN-STEVENSON et al. 2006). Both of these models have a conserved 
innate immune system which is responsible for fighting fungal infections; thus these 
model organisms are widely used to study virulence factors (MYLONAKIS and ABALLAY 
2005).  C. elegans has been shown to be useful for performing in vivo, whole animal 
high throughput screens for identifying antimicrobials (BREGER et al. 2007).   
We have previously reported a pathogenesis assay in which we infect C. elegans with 
C. albicans and observe the deformed anal region (Dar) phenotype in the worms, which 
we use as biomarker for altered virulence (JAIN et al. 2009).  This is a simple, 
straightforward assay that is also amenable to high throughput screening for fungal 
virulence factors.  Using this assay, we have screened ~1200 mutants from a knockout 
library of Candida clones submitted to FGSC by Dr. Aaron Mitchell.  We identified 7 
virulence factors.  Three of these genes (CMP1, IFF11 and SAP8) are known virulence 
factors.   In addition we identified 4 novel genes (orf19.1219, orf19.6713, DOT4 and 
ZCF15).  Not much is known about these genes and provides a foundation for future 
work in order to decipher their role in fungal pathogenesis.  
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4.2  MATERIALS AND METHODS 
Strains, media and growth conditions 
The C. albicans strains used are listed in Table 1.  Strains were grown overnight in 
yeast extract-peptone-dextrose (YPD) at 37°C. The C. elegans strains were grown at 
20°C on nematode growth agar medium (NGM) spotted with Escherichia coli OP50 and 
maintained as described previously (BRENNER 1974).  E. coli OP50 was grown overnight 
in Luria broth at 37°C.  The C. albicans knockout library was obtained from the fungal 
genetics stock center (MCCLUSKEY et al. 2010). 
Table 1: Strains used in this study 
 Strains  
Relevant 
Genotype 
Complete Genotype  
C. elegans strains 
N2 Bristol Wild type Wild type 
C. albicans strains 
SC 5314 Wild type Wild type 
SN250 
Reference 
strain 
Arg4 ∆/∆ 
his1∆/his1 ∆, leu2 ∆::C. dubliniensis HIS1 /leu2 ∆::C. maltosa 
LEU2, arg4 ∆  /arg4 ∆, URA3/ura3 ∆::imm434, IRO1/iro1 
∆::imm434 
MS1- 335 orf19.1219∆/∆ 
his1∆/his1∆, leu2∆/leu2∆, arg4∆/arg4∆, URA3/ura3 
∆::imm434, IRO1/iro1∆::imm434, 
orf19.1219∆::C.dubliniensisHIS1/orf19.1219∆::C.maltosaLEU2 
MS1- 596 dot4∆/∆ 
his1∆/his1∆, leu2∆/leu2∆, arg4∆/arg4∆, URA3/ura3 
∆::imm434, IRO1/iro1∆::imm434, 
dot4∆::C.dubliniensisHIS1/dot4∆::C.maltosaLEU2 
MS1- 221 sap8∆/∆ 
his1∆/his1∆, leu2∆/leu2∆, arg4∆/arg4∆, URA3/ura3 
∆::imm434, IRO1/iro1∆::imm434, 
sap8∆::C.dubliniensisHIS1/sap8∆::C.maltosaLEU2 
MS1- 529 zcf15∆/∆ 
his1∆/his1∆, leu2∆/leu2∆, arg4∆/arg4∆, URA3/ura3 
∆::imm434, IRO1/iro1∆::imm434, 
zcf15∆::C.dubliniensisHIS1/zcf15::C.maltosaLEU2 
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Egg Preparation 
Three wild type worms in the L3/L4 stage were transferred to each of two NGM agar 
plate containing E. coli OP50 and grown at 20°C for four days. On the day of the 
experiment worms were washed off the plates with M9 buffer and centrifuged at 900X g 
for 2 min. The supernatant was removed, and the worms were then resuspended in a 
bleach solution (1:4 dilution of commercial bleach (5.25%) containing 0.25 M sodium 
hydroxide). The worm suspension was mixed gently by inversion for 3 min, and 
centrifuged for 2 min at 2,000X g.  The pellet was washed and centrifuged with M9 
buffer at 2,000X g for 2 min and then finally resuspended in 500 µl M9 buffer. The egg 
suspension was diluted or concentrated with M9 buffer as required to obtain 
approximately 30-40 eggs/5µl. 
 
Pathogenesis Assay 
E. coli and Candida strains were grown overnight at 37°C. Culture aliquots were 
centrifuged at full speed for 1 minute in a table top microcentrifuge and the supernatant 
was removed. Pellets were washed twice in sterile deionized water, and finally 
resuspended to a final concentration of 200 mg/ml and 10 mg/ml, respectively.  A 
mixture of 10 µl of a 50-mg/ml streptomycin sulfate stock, 7 µl of distilled water, 2.5 µl of 
E. coli and 0.5µl of Candida was spotted on to each NGM plate. E. coli spotted plates 
was used as control. Finally, 5 µl of C. elegans egg suspension was transferred to each 
plate. Plates were then kept in a 20°C incubator and were observed over next 5 days.  
Screen was done on a single plate/mutant.  Experiments other then the screen were 
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done in triplicate. Student t-test was used to check the statistical significance of the 
differences observed between wild type and other Candida strains. 
 
4.3  RESULTS 
 
Screening the Candida transposon mutagenized library 
We have previously reported a pathogenesis assay in which C. elegans is infected by 
the pathogen C. albicans.  One consequence of this infection in C. elegans is an 
induction of the deformed anal region (Dar) phenotype.  Using Dar as a biomarker for 
infection, number of worms showing this phenotype in response to infection can be 
quantitated.  In order to identify novel virulence factors and thus new pathways that may 
be important for virulence, we screened ~1200 mutants in the Mitchell Candida 
transposon library (NOBILE and MITCHELL 2009).   The strategy that was used to do the 
screen is shown in the schematic (Figure 1).  
 
 
 
 
 
 
Figure 1.  Schematic of the strategy used to screen the mutant library  
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The library was created by insertion of the Tn7-UAU1 cassette into C. albicans genomic 
library by in vitro transposition.  The UAU1 cassette consists of a functional ARG4 gene 
flanked by nonfunctional URA3 deletion derivatives.  Insertion of the cassette into the 
first allele gives the Arg+, Ura- phenotype.  Due to mitotic gene conversion, 
heterozygous insertion of UAU1 becomes homozygous and has to be selected for 
URA3 transformants.  In this second step UAU1 cassette can recombine and excise 
ARG4 and yield functional URA3 and the transformants screened for Arg+, Ura+ 
phenotype (Figure 2).  Thus, use of this cassette results in the formation of homozygous 
mutants from single C. albicans transformation.  The library consists of a collection of 
homozygous mutants representing genes coding for transcription factors, cell wall 
proteins and kinases. 
 
Figure 2.  Genetic properties of UAU1 cassette. (A) UAU1 conversion to URA3 due to 
recombination excision of ARG4.  (B) Selection for double disruption results in formation 
of homozygous insertion mutants. Modified from (NOBILE and MITCHELL 2009) 
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From the screen we identified 7 mutants that induced a reduced percentage of worms 
with Dar, and thus showed altered virulence.  These are listed in Table 2.  Of these, 3 
(CMP1, IFF11 and SAP8) are known to be involved in virulence.  The novel genes 
(orf19.6713, orf19.1219, DOT4 and ZCF15) that we have identified through our screen 
have never been implicated before for their role in virulence.  This is the first time where 
we are suggesting their potential role as virulence factors. 
Table 2: List of mutants identified in the screen for their role in pathogenesis 
ORF # % Dar Description 
Wild type 90.6 ± 2.5 
 
Known genes  
orf19.6033 
(CMP1)  44 Catalytic subunit of calcineurin  
orf19.12854 
(IFF11)  46 Secreted protein required for cell wall structure  
orf19.242 
(SAP8)  68 
Secreted Aspartyl Proteinase highly expressed 
in opaque cells  
Novel genes  
orf19.6713  30 Uncharacterized  
orf19.1219  36 Uncharacterized  
orf19.3370 
(DOT4)  48 
Cell surface protein in hyphal cells similar to 
Ubiquitin hydrolase  
orf19.2753 
(ZCF15)  47 Predicted Zinc finger protein  
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From previous work we know that Iff11, a secreted protein is important for organization 
of cell wall and the null mutant is attenuated in virulence in the mouse model (BATES et 
al. 2007).  Similarly, from the work previously done on Cmp1, which codes for the 
catalytic subunit of calcineurin, is essential for virulence in a mouse model for systemic 
candidiasis (BADER et al. 2003).  Sap 8, a secreted aspartyl proteinase, on the other 
hand, has shown to be preferentially expressed in vaginal Candida infection rather than 
oral infections (NAGLIK et al. 2003).  Of the novel genes, orf19.1219 and orf19.6713 are 
uncharacterized, with probable nucleic acid and zinc ion binding motifs identified 
through computational analysis for the latter.  Dot 4 codes for a protein which might be a 
homologue of Ubiquitin hydrolase and the protein specifically localizes to surface of 
hyphal cells (URBAN et al. 2003).  Zcf15 is also uncharacterized, with a predicted zinc 
finger protein with a probable sequence specific transcription factor activity.  
In order to confirm the phenotypes that we were observing were caused by loss of 
function; we used gene deletion mutants for some of the genes and repeated the Dar 
assay.  We tested sap8∆, orf191219∆, dot4∆ and zcf15∆ mutants and compared them 
to the respective wild type SN250 strain in the Dar assay.  We observed that all the 
above mentioned mutants showed significant reduction in Dar (Fig.3, p<0.05 for all 
strains) compared to the wild type, indicating these mutants indeed show altered 
virulence.   
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WT 
(n=93) 
sap8 ∆ 
(n=86)  
orf19.1219 ∆ 
(n=83)  
dot4 ∆ 
(n=89)  
zcf15 ∆ 
(n=93)  
 
                               
 
       
Figure 3.  Wild type worms were exposed to sap8 ∆, orf19.1219 ∆, dot4 ∆, zcf15 ∆ 
deletion mutants and their corresponding wild type Candida strains in order to confirm 
the results from the screen. % worms that exhibited Dar were scored on Day 3 and the 
data plotted.  All mutant strains show significant reduction (p<0.05) compared to the wild 
type.  
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4.4  DISCUSSION 
Large scale screens for identification of virulence factors can lead to identification of 
novel genes with role in pathogenesis as well as identification of pathways and new 
interconnectivity between known pathways.   C. elegans provides us with an excellent 
tool to do an in vivo whole animal screen to look for the virulence determinants of.  
Using the pathogenesis assay described in this work, we have screened a C. albicans 
mutant library just by feeding the worms with the specific mutant strains.  Though not 
part of this work, it is feasible to screen for host immune effectors in C. elegans using a 
slightly modified version of the assay and feeding them the C. elegans RNAi library.  
Despite these advantages, we have to remember that the gut of the worm provides a 
specific niche for Candida to colonize in.  We also know from previous work, that in 
some cases that is a differential expression of genes depending on their surroundings.  
For example in case of PHR1 and PHR2 which encode a glycosidase, the virulence 
phenotype of a phr1 null mutant is attenuated in systemic infections but not in vaginal 
infections.  In contrast phr2 null mutants are virulent in systemic situation but avirulent in 
vaginal infection model (DE BERNARDIS et al. 1998; SAPORITO-IRWIN et al. 1995).  This 
indicates that in our screen along with novel potential virulence factors, we might not be 
able to pick all known virulence factors present in the library.  Instead we will pick those 
that are known to be required for fungal pathogenesis in an environment similar to the 
one present in C. elegans gut.  
Through this screen we have identified 3 genes (CMP1, IFF11 and SAP8) known for 
their role in fungal virulence, and 4 genes (orf19.1219, orf19.6713, DOT4 and ZCF15) 
that were not known to play a part in fungal pathogenesis.   Mutation in these 4 genes 
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leads to altered virulence in the nematode.  Most of these genes are not characterized 
and the information available on the others is very limited.  Despite this paucity of 
information of their role in C. albicans, homologues of these genes in S. cerevisiae are 
known and have been well studied.   Extrapolation from their function in S. cerevisiae 
can help us speculate about their gene function in Candida, and focus our study.   
The homolog of orf19.1219, an uncharacterized gene in C. albicans, is the S. cerevisiae 
RKR1 gene.  In S. cerevisiae, the product of RKR1 is a conserved nuclear RING 
domain protein that modulates chromatin structure, function, and transcription. This 
complex is required for several histone modifications and transcription, and cells lacking 
this gene show impaired sub-telomeric gene silencing (HOYER 2001).  
In regards to DOT4 we have very little information available. For C. albicans we do 
know that the gene codes for a protein that is similar to a Ubiquitin C-terminal hydrolase 
which normally localizes to the surface of hyphal cells (URBAN et al. 2003). This 
suggests that the gene plays a role during pathogenesis, as hyphal formation is one of 
the main traits of pathogenesis.  Its homologue in S. cerevisiae is a ubiquitin protease 
known to be important for sub-telomeric gene silencing and chromatin modification 
(KAHANA and GOTTSCHLING 1999).  Loss of this gene in S. cerevisiae leads to 
expression of sub-telomeric genes.  Thus it seems that its function is contrary to that of 
RKR1 in S. cerevisiae.     
ZCF15  was identified in an In silico screen of the C. albicans genome, as an ORF 
possessing  a Zn(II)(2)C(6)-type binuclear cluster that might be involved in DNA 
recognition (MAICAS et al. 2005).  Thus, it possesses a DNA binding domain and may 
behave as a transcription factor. There is currently some debate as to its homologue in 
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S. cerevisiae.  According to the Candida Genome Database, its homologue in S. 
cerevisiae is PDR1, which is a transcription factor, but according to the orthology 
website of Broad Institute (http://www.broadinstitute.org/regev/orthogroups/), the 
nearest homologue is PUF2, which is a RNA binding protein.  This indicates that 
detailed studies need to be done in order to characterize this gene.  Some preliminary 
work does indicate that deletion of this gene in C. albicans leads to more filamentation 
compared to the wild type.   
The final gene identified in the screen was orf19.6713 which is uncharacterized.  
Computational analysis indicates that it might have a nucleic acid binding domain, while 
the ortholog search on the Broad website identifies MSB1 in S. cerevisiae as its 
ortholog. Msb1 is a protein involved in positive regulation of β1-3 glucan and Pkc1-
MAPK pathways. 
The above information clearly reflects the need to characterize these genes and study 
their role in pathogenesis. 
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Chapter 5 
Small molecule screen to identify inhibitors of C. albicans adhesion. 
Use of catheters and intravenous devices is one of the main causes of disseminated 
Candida infection. Use of these devices compromises the physical barriers to function, 
and patients who undergo implantation are already immunocompromised.  Simple use 
of a urinary catheter by immunocompromised patients can lead to fatal systemic 
infections. 
These devices can act as an inert substrate for adhesion of microbes, including C. 
albicans, and thus provide a platform on which the microbes can grow and spread.  The 
process of biofilm formation is generally divided in multiple steps.  Once the Candida 
cells bind to the inert surface (Adhesion) they start dividing and undergoing 
morphological changes to hyphal and pseudohyphal forms (Initiation).  This is followed 
by the production of extracellular material (shown in green).  This results in the 
formation of a biofilm (Figure 1).  Candida from these biofilms can then disperse and 
either attach to host surfaces or get released in blood from where they can infect 
multiple organs. 
 
 
 
Figure 1. Steps involved in biofilm formation in C. albicans.  Modified from (FINKEL and 
MITCHELL 2011) 
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Biofilms are relatively more resistant to antifungal drugs or host immune responses.  
Currently, research has been focused on developing new strategies to inhibit biofilm 
formation and one of these strategies is coating the devices with a compound that can 
prevent adhesion and thus, biofilm formation.  Many such compounds have been 
suggested but most of them have not been successful in fulfilling their roles.  The 
following chapter describes identification of one such putative compound. 
I was involved in doing the screen, part of which is shown in figure 3. I was responsible 
for designing, collecting the data and its analysis in figure 5.  I was also involved in 
designing rest of the experiments and analysis of data. 
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5.1  Introduction 
Candida albicans is a fungus that is part of normal human microbial flora found on the 
skin, mouth, gastrointestinal tract and vagina.  Under certain conditions of a 
compromised immune system e.g., patients undergoing organ transplant, chemotherapy 
treatment or suffering from AIDS, this commensal can become pathogenic and cause 
disease (DUPONT 1995; WEIG et al. 1998).  It can cause infections ranging from mild 
mucosal infection to lethal systemic infections.   C. albicans is the 4th leading cause of 
blood stream or systemic infection (EDMOND et al. 1999) and has a high mortality rate of 
50% in the cases of nosocomial infections (GUDLAUGSSON et al. 2003). Currently ~ $ 1 
billion per year is spent on treatment of nosocomial infection (MILLER et al. 2001). 
Systemic or disseminated candidiasis in most cases is observed in 
immunocompromised patients, and one of the main causes of this is the presence of 
contaminated intravascular devices and catheters (VELASCO et al. 2000).  Candida from 
these devices is disseminated into the bloodstream and spreads by infecting multiple 
organs.  The first course of action for these fungal organisms in the blood is to adhere to 
the endothelial surface and then to penetrate the endothelial lining of the blood vessel 
and the extracellular matrix; in this way they can infect multiple organs.   
Adhesion to the host cell surface, either epithelial or endothelial, is a first and critical 
step in establishing a fungal infection.   From the multiple studies that have been 
conducted in relation to the adhesion of Candida to the host surface, it is believed that 
the yeast form cells of Candida are most likely responsible for adhesion either to 
epithelial/endothelial cells (BENDEL et al. 2003; SAVILLE et al. 2003) or to the inert 
surface.  This is then followed by morphogenesis of cells from the yeast form into the 
109 
 
hyphal form which then further helps in the invasion of the host tissue or forming 
biofilms.  Biofilm associated infections normally do not respond to conventional 
treatment and it sometimes becomes necessary to remove the devices in order to 
completely treat the infection (BAUTERS et al. 2002).   There are multiple strategies that 
are being used to prevent biofilm-associated infections (HETRICK and SCHOENFISCH 
2006); one of these consists of coating the devices with chemicals (WU and GRAINGER 
2006).  Some antifungal compounds have been used as a coating on these catheters 
(DAROUICHE et al. 2006; PIGNO et al. 1994).  Other studies have used nystatin, or zinc 
pyrithione as coating material (DE PRIJCK et al. 2010).  Nystatin is an antifungal that 
binds to ergosterol, a fungal specific component of cell membrane and forms pores 
while zinc pyrithione blocks the proton pump and disrupt membrane transport. 
Thus there is a need to identify better coating materials or compounds that can prevent 
adhesion and thus biofilm formation.  This work is focused on screening a library of 
small molecule compounds and identifying some compounds that could be potentially 
used as coating material to prevent biofilm formation. 
 
5.2  Material and Methods 
Strains and Growth conditions 
The C. albicans strains used were the wild type, SC5314, and the mutant edt1-/- which 
is defective in adhesion.  The strains were grown overnight at 30oC in YPD or Synthetic 
complete (SC) medium with 0.15% glucose depending on the experiment. The C. 
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elegans wild type strain N2 was grown at 20°C on nematode growth agar medium 
(NGM) spotted with Escherichia coli OP50 and maintained as described previously 
(BRENNER 1974).   E. coli OP50 was grown overnight in Luria broth at 37°C.  
 
Adhesion Assay for the Screen 
A 5 ml starter culture of SC5314 and two, 5ml starter cultures of edt1-/- in SC+0.15% 
glucose media at 30oC were started 2 days before the experiment.  A day before the 
experiment, from these starter cultures a 100ml culture was started for each strain, in 
SC+0.15% glucose media at 30oC.  On the day of the experiment OD600nm was 
measured for both of the cultures.  Appropriate number of cells  for each strain were 
spun down and resuspended in fresh SC+0.15% glucose media to a final concentration 
of 0.5 OD/ml. 
200µl/well of 0.5 OD/ml edt1-/- culture was added to the first column of a 96 well 
Immulon ELISA plate. Then 200µl/well of 0.5 OD/ml SC5314 culture was added to 
columns 2 through 12.  This was followed by robotic addition of 2µl of compound each, 
which were dissolved in DMSO, to each well from columns 2 through 11 and of DMSO 
for the negative control in column 1 and positive control in column 12.  The cells and the 
compounds were mixed robotically 3 times by pipetting the mixture up and down.  The 
plates were then covered with Al foil and allowed to incubate at 37oC for 4 hours. The 
content of the wells were then decanted and 50 µl of 0.5% crystal violet was added to 
each well of the plate.  The plates were covered again and allowed to sit at room 
temperature for 45 minutes.  This was followed by decanting the contents of the well.  
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Plates were then gently rinsed by submerging them in an ice bucket filled with distilled 
water and then decanting the water to wash off the excess dye.  This was repeated 4 
more times and then wells were rinsed with water.  The rinsing was done 5 more times.  
The plates were then gently tapped on a paper towel to remove any excess water and 
the sides and the bottom were wiped down.   200 µl of 75% Methanol was then added 
to each well of the plate.  The plates were allowed to sit for 30 minutes at room 
temperature and then OD was taken at 590nm.  Plate with wells that showed significant 
less color and OD values were photographed. 
 
Egg Preparation 
Three worms in the L3/L4 stage each were transferred to two NGM agar plate 
containing E. coli OP50 and grown at 20°C for four days. On the day of the experiment 
worms were washed off the plates with M9 buffer and centrifuged at 900X g for 2 min. 
The supernatant was removed, and the worms were then resuspended in a bleach 
solution (1:4 dilution of commercial bleach (5.25%) containing 0.25 M sodium 
hydroxide). The worm suspension was mixed gently by inversion for 3 min, and 
centrifuged for 2 min at 2,000X g.  The pellet was washed and centrifuged with M9 
buffer at 2,000X g for 2 min and then finally resuspended in 500 µl M9 buffer. The egg 
suspension was diluted or concentrated with M9 buffer as required to obtain 
approximately 30-40 eggs/5µl. 
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Pathogenesis Assay 
E. coli and Candida strains were grown overnight at 37°C. Culture aliquots were 
centrifuged at full speed for 1 minute in a table top microcentrifuge and the supernatant 
was removed. Pellets were washed twice in sterile deionized water, and finally 
resuspended to a final concentration of 200 mg/ml and 10 mg/ml, respectively.  A 
mixture of 10 µl of a 50-mg/ml streptomycin sulfate stock, 7 µl of distilled water, 2.5 µl of 
E. coli and 0.5µl of Candida was spotted on to each NGM plate. Drugs in a final 
concentration of 12.5 µM were added to the mix.  E. coli spotted plates were used as 
control. Finally, 5 µl of C. elegans egg suspension was transferred to each plate. Plates 
were then kept in a 20°C incubator and were observed over next 5 days.  All the 
experiments were done in triplicate. Student t-test was used to check the statistical 
significance of the differences observed between wild type and other Candida strains. 
 
Macrophage Growth Inhibition Assay with the Compounds 
Macrophage cell line RAW 264.7 (ATCC) was used in the assay.  The cell line was 
maintained in DMEM supplemented with 10% fetal bovine serum (FBS).  The protocol 
was slightly modified from the original (LOPES DA ROSA et al. 2010). Briefly, 
macrophages on reaching 80-90% confluence were scraped and brought up in DMEM 
supplemented with 10% FBS, 100 U/ml Penicillin, and 100µg/ml Streptomycin. 2 X 106 
macrophage cells were placed in a 35mm2 plate and allowed to adhere for 5 hours.  
Candida strain SC5314 was grown overnight at 37˚C and diluted 1:10 and allowed to 
grow for another 5 hours.  Candida cells were then washed with supplemented DMEM 
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and were added to the plates containing macrophages in a ratio of 1Candida:15 
macrophage cells to a final volume of 2 ml.  SC5314 was also grown in parallel without 
macrophages to calculate % survival. Compounds of interest in specific concentrations 
were added to each plate so that each sample concentration was tested in duplicate or 
triplicate. DMSO alone at a volume similar to that of compounds was also added as 
control to SC5314 and SC5314 – macrophage co- cultures in the absence of 
compounds. The plates were incubated overnight (15-16hours) at 37˚C and 5% CO2.  
Cells were then brought up to 24 ml in a tube using 0.05% Triton X-100 (v/v) in water to 
osmotically lyse the macrophage cells.  Dilutions were prepared and plated on YPD 
plates and grown overnight at 37˚C.  Colony forming units (CFU) were counted and 
percentage survival was calculated by taking the ratio of CFU from co culture of 
Candida and macrophage to the CFU obtained for Candida alone.  
 
5.3  Results 
 
Screening a Small molecule library to identify inhibitors of C. albicans adhesion 
to an inert surface. 
Traditionally drug discovery begins with target identification - a protein that plays a key 
role in the disease.   The next step is focused on developing assays used to identify 
small molecules that will inhibit the target protein. This is further followed by in vitro and 
in vivo toxicity and efficacy studies as part of pre-clinical trials.  This target-based 
approach can sometimes become very lengthy and is one of the reasons for the slow 
adoption of new drugs.  We took an alternative approach that is based on function, 
 rather than a single protein.  We screened a small molecule library (UMass Medical 
School, Worcester) of 30,000 compounds (
cells of C. albicans wild type strain SC5314 in 96 well plates.  The positive
wells that showed >50% inhibition measured as final OD at 590nm (Figure 3, shown in 
red).   We used a modified crystal violet adhesion assay that measures the extent of 
adhesion of C. albicans cells to an inert polystyrene surface 
C. albicans edt1-/- mutants lacking a protein that facilitates adhesion to surfaces was 
used as positive control, while wild type 
negative control. 
  
 
 
 
 
  
 
 
Figure 2.  Flow chart of the steps 
Compounds that were able to inhibit 
considered positive hits.  1.3% of the library gave a positive result. These compounds 
were then analyzed based on their commonality and differences in the structure (Figure 
2).  Through this structural analysis, we picked a family of 26 related compounds (Table 
1) for follow up studies.  Structural analysis was later on followed up by a study of dose 
dependence of these 26 compounds in the crystal violet assay.  This enabled us 
50 µM) together with 0.1 OD of log phase 
(REYNOLDS
C. albicans SC5314 with DMSO was used as 
taken to identify an inhibitor of adhesi
Candida adhesion by more than 50% were 
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 and FINK 2001).  
on. 
to 
 focus on 3 compounds, whose ids in Chembridge 
(compound 5) and 7140676 (compound 9)
 
 
 
 
 
Figure 3.  Drugs causing more than 50% inhibition in adhesion of SC5314 were 
selected as positive hits.  SC5314 without the drug was used as a positive control while 
edt1-/- without the drug was the negative control. Since the drug added was dissolved in 
DMSO, the same concentration of the solvent was also added in control wells. (A) A 
photograph of a representative plate that was observed during the screen. (B)  
Corresponding OD590nm values for the plate shown above.  The difference in the color 
intensity correlates with the range of inhibition.  As we can see the well with red circle 
was considered a positive hit but the one with the black circle was not.
A 
B 
are 6714151 (compound 4)
. 
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Compound 4 and 5 decrease the extent of C. albicans infections in C. elegans. 
We have previously reported a pathogenesis assay in which we infected the nematode 
Caenorhabditis elegans with the pathogen C. albicans and quantitated the number of 
worms showing the disease phenotype Dar (deformed anal region). Using this assay we 
were able to screen for novel virulence factors in C. albicans which are important for 
virulence.  Using the same assay we wanted to test the ability of these drugs in 
inhibiting the infection process in C. elegans. We exposed the eggs to   Candida alone 
or with drug in 12.5 µM concentration and quantitated for Dar on Day 4.  We observe 
that compound 4 and 5 were able to significantly reduce the number of worms exhibiting 
Dar (Figure 4).  This shows that compounds 4 and 5 do play some role in inhibiting 
fungal infection in C. elegans. 
 
Figure 4.  Compound 4 and 5 inhibit Candida infection in C. elegans.  Worm eggs were 
exposed to mixed lawns of E. coli and Candida without and with the compounds 4, 5 
and 9 at 12.5 µM concentrations and observed for Dar on day 4.  Compounds 4 and 5 
significantly (p<0.05) reduced the % of worms with Dar compared to the worms exposed 
to WT strain without the compound.    
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Figure 5.  Compound 4 shows a dose dependence increase in the % survival of C. 
albicans when exposed to RAW264.7 macrophages.  SC5314 was exposed to 
macrophages in the presence of the solvent DMSO as control and (A) dose 
dependence of compounds 4, 5 and 9.   Since the experiment was performed in 
duplicates and an observable change was see with compound 4, the experiment was 
repeated in triplicate with (B) dose dependence of compound 4.  There was a significant 
increase in the Candida survival. 
 
A 
B 
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Compound 4 inhibits Candida attachment to mammalian phagocytes. 
In order to assess compounds 4, 5 and 9 as potential inhibitors of adhesion in 
mammalian cells, we exposed murine macrophage cell line RAW264.7 to C. albicans 
SC5314 in 15:1 ratio with and without the drugs at different concentrations and % 
Candida survival was calculated.  We hypothesized that Candida will not attach to 
phagocytes in the presence of the drug and will escape phagocytosis.  Compounds 5 
and 9 were not significantly different compared to DMSO control. In presence of 
compound 4, we observed a ~ 5 times increase in the % survival of the Candida cells 
(Figure 5A).  Compound 4 was retested at concentrations 2 and 12 µM and exhibited 
dose dependent inhibition of Candida adhesion (Figure 5B).  Thus, compound 4 affects 
the adhesion of Candida to macrophages and prevents phagocytosis.   
 
5.4  Discussion 
Adhesion to the host mucosal epithelium is required for the fungal organism to establish 
itself, colonize and cause infection.  If not treated, in some very few cases these 
mucosal infections can become systemic.  Chances of a systemic infection are higher 
with the use of intravascular devices and catheters.  Candida forms biofilms on these 
devices and thus obtains access to the bloodstream of the patients.  Any compound that 
can inhibit the adhesion of Candida to these inert surfaces can potentially be used as 
one of the preventives for systemic infections.   
To identify such compound we screened a library of 30,000 compounds and identified 
one compound which has the potential of being an inhibitor of Candida adhesion.  
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Following the steps in the scheme (Figure 2), we eventually tested 3 compounds in an 
in vitro mammalian model of phagocytic cells and identified a potential role of compound 
4.  Further testing confirms a dose dependent effect of compound 4 on adhesion of 
Candida to macrophages. This means that the drug might be altering the fungal cell 
surface in such a way, that it can no longer adhere to macrophages. 
These exciting results show the potential of compound 4 as an inhibitor of adhesion.  
The next step would be to test the adhesion of C. albicans on human epithelial cells, 
silicon catheter material and other implant materials in the presence of compound 4. 
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Table 1. List of 26 compounds 
Compound 
# 
Compound 
IDs Structure 
Molecular 
Formula 
Mol. 
Weight 
1 6177408 
 
C18H18BrN3O3 404.258 
2 6870699 
 
C21H18FNO4 367.37 
3 6139415 
 
C18H16ClF2N3O
3 395.788 
4 6714151 
 
C18H18ClN3O3 359.807 
5 7021797 
 
C26H29N3O3S 463.592 
6 7288338 
 
C19H16Cl2N2OS 391.314 
7 7291583 
 
C28H28N2O3 440.534 
8 7052098 
 
C16H14BrNO3 348.191 
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9 7140676 
 
C17H16Cl2N6 375.255 
10 6942569 
 
C14H11Cl2N3OS 340.228 
11 6988606 
 
C14H11FN2O4 290.247 
12 7115759 
 
C23H32N4O2S 428.591 
13 7024394 
 
C18H21N3 279.379 
14 6777751 
 
C14H11BrClNO2 340.6 
15 6886186 
 
C19H13N3O2S 347.39 
16 5605598 
 
C21H19Cl2N3O2 416.3 
17 6873245 
 
C19H23NO2 297.391 
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18 7111893 
 
C22H19N3OS2 405.536 
19 7146132 
 
C18H19N3OS 325.428 
20 7319890 
 
C18H29NO 275.429 
21 6937280 
 
C23H32N2O4S 432.576 
22 7113600 
 
C27H27N3O4 457.521 
23 
5742793 
 
 
C21H25N3O3 367.442 
24 5221077 
 
C17H16BrN3O3 390.231 
25 7239106 
 
C19H21ClN2O 328.836 
26 7276058 
 
C18H19ClN2O 314.809 
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Chapter 6 
Significance and Future Directions 
6.1  Significance 
In this work, I have demonstrated the utility of the pathogenesis assay in multiple ways 
(Figure 1).  First I have shown that the assay is useful in identification of virulence 
determinants using a candidate gene approach.  Thus, I identified Cap1 to be important 
in fungal response against stress caused by ROS (Chapter 3).   
 
Figure 1. An overview of various ways in which pathogenesis assay was used. 
 
I have also shown that using the assay it is possible to screen a library of Candida 
mutants.  Through such screen we can look for novel virulence factors and pathways 
that add to the repertoire of Candida, that it uses to overcome the selective pressure in 
Assay
Virulence 
determinants
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ZCF15
orf19.1219
orf19.6713
Host immune 
effectors
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Antifungal 
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the host environment.  We screened a library of ~1200 C. albicans insertion mutants, 
and identified 4 novel (orf19.1219, orf19.6713, DOT4 and ZCF15) genes that potentially 
play a role in fungal infection (Chapter 4).   
Second, I can use the assay to identify host immune effectors that are involved in 
resistance against Candida infection.  I have shown that BLI-3 is an important part of 
host innate immune response, as it produces ROS to counteract Candida infection 
(Chapter 3).  Although not part of this work, this assay after some modifications can also 
be employed to screen the C. elegans RNAi library to order to identify the modulators of 
innate immune responses during fungal infection.   
Third use of this assay is for drug screens or to test for potential drugs in a whole animal 
model.  Families of related (same scaffold) compounds were identified through an 
adhesion screen of 30,000 compounds, for their ability as potential inhibitors of C. 
albicans adhesion to biological and inert surfaces.  These compounds were further 
tested in the pathogenesis assay for their ability to reduce infection of C. albicans in C. 
elegans (Chapter 5).   
Finally, using the survival assay to test for the mortality caused by infection, I could 
observe disparity in the different C. albicans fluconazole resistant strains isolated from 
AIDS patients (Appendix).  This shows that we can study the differences in the Candida 
strains that have been exposed to the host environment and evolved to counter the 
select pressure of the environment.   
Candida albicans has 8 chromosomes and belongs to the pre duplication clade of fungi 
(Figure 2) but its most important characteristic is that the genome exhibits a high degree 
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of plasticity. This plasticity includes gross chromosomal rearrangements, aneuploidy 
and loss of heterozygosity (LOH) (RUSTCHENKO 2007).  C. albicans reproduces through 
asexual clonal division (IWAGUCHI et al. 1992) and even though most of its mating and 
meiosis machinery is retained (TZUNG et al. 2001), meiosis is never observed (MAGEE 
and MAGEE 2004).  
  
Figure 2. C. albicans belongs to the pre duplication clade.  Boxed region is the clades 
of interest.  WGD – Whole genome duplication. Adapted from (FITZPATRICK et al. 2006) 
WGD 
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C. albicans have mating type like alleles (MTL) a and α.  In some cases strains that are 
homozygous for MTL, which only occurs in 3 to 10% of clinical isolates are mating 
competent (LEGRAND et al. 2004).  The strains that mate become tetraploid and undergo 
random loss of multiple chromosomes until they reach a near diploid state (ALBY et al. 
2009).  This parasexual cycle provides an alternative to meiosis and gives rise to 
genomic diversity.  Along with these diversity arising in clinical isolates through 
parasexuality, current models support the occurrence of adaptive mutations that can 
occur, e.g., during host pathogen interaction or with the acquisition of drug resistance 
(BENNETT and JOHNSON 2005).   
Maintenance of heterozygosity is one of the ways that C. albicans maintains genetic 
variability.  Despite this, LOH is very common and is considered to be an important 
factor in acquiring azole resistance.  Homozygosity of hyperactive alleles like ERG11 
(encodes target of azole drug) is associated with increased azole resistance (WHITE 
1997c).  Furthermore some of the evolved clinical isolates that showed azole resistance 
and were confirmed for LOH were tested in our assay and compared to their progenitors 
which were drug sensitive.  Our assay clearly shows an increase in mortality of C. 
elegans exposed to LOH strains compared to the progenitors (Appendix, Figure 3).   
Thus it will be interesting to study the different aspects of Candida genome diversity 
which can potentially lead to increased virulence in our pathogenesis assay. 
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6.2  Future Directions 
The work presented in this thesis has helped us gain insightful knowledge about fungal 
pathogenesis.  Use of pathogenesis assay and other corroborating experiments has 
answered a few of the questions in the field but has raised more queries that need to be 
addressed. 
The 4 potential virulence factors, orf19.1219, orf19.6713, Dot 4 and Zcf15 that were 
identified in the screen, are uncharacterized in C. albicans. Their roles can only be 
speculated from their homologs in S. cerevisiae.   Future work would entail the 
characterization of these genes and assessment of their role in fungal pathogenesis.  
Apart from the normal tests that are done to characterize a mutant such as study shape 
of the mutant cells and colonies, and compare growth in different media, we need to do 
genome level studies to identify their protein targets for interaction.  Extrapolating their 
role in S. cerevisiae, either these proteins are transcription factors or enzymes important 
in the ubiquitination pathway.  Either way they could target a number of proteins and 
thus be responsible for their co-regulation.  Identifying these targets will further help us 
tease out the specific steps for which these factors might be important.  Microarrays are 
one of the ways through which we can identify their direct or indirect targets, as 
expression of these targets will either be substantially lowered or raised in the mutants 
compared to the wild type.   
The one limiting factor of our assay is that quantification of the biomarker, Dar can be 
time consuming, making the use of this assay in high throughput  screenings a little 
difficult if not impossible.   There are now automated approaches available to image 
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thousands of samples per day.  Using these approaches combined with cell imaging 
software’s  like CellProfiler (CARPENTER et al. 2006) could allow us to do functional 
genomics or chemical screens in a high throughput manner.  Using the software we can 
quantitatively address complex morphological changes such as cell/organelle shape or 
potentially Dar phenotype.  Optimizing this software to “read” Dar will truly make the use 
of patho-assay a high throughput assay for screening fungal virulence factors, host 
immune effectors or chemicals that could potentially have a role as an antifungal. 
High-throughput antifungal screens are normally performed in vitro and then followed up 
by a much smaller scale testing in in vivo models.  Use of this assay will provide us with 
the means to skip the first step and directly screen the potential drugs in an in vivo 
manner.  Furthermore, use of E. coli in the assay also provides us with the potential of 
utilizing the C. elegans RNAi collection library to identify probable, universal or specific, 
host immune effectors and pathways that are activated during fungal infections in a high 
throughput fashion. 
We also observed the role of evolved fluconazole resistant strains in fungal infection 
through our assay.  The normal Candida strains in the human body are under selective 
pressure from host immune responses, and any favorable genetic changes they 
experience in the host environment may make it possible for them to spread and infect.  
Attempts to control this process in humans through activation of host immune 
responses or from administration of antifungals, has led to the evolution of these 
organisms.  Our assay would be a great advantage in studying the evolution of these 
strains in whole animal model. 
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Appendix 
 
Resistance of C. albicans to antifungal drugs is a growing problem in the medical field.  
A study was done by Perea et. al. in 2001 to identify the molecular mechanism for azole 
resistance.  They isolated the pathogen from AIDS patients suffering from   
oropharyngeal candidiasis.  An initial sample (Progenitor) was collected, patients were 
administered the drug, and a second sample (Evolved) was then collected from the 
patients that were not cured by the drugs. In some cases, more samples (Evolved) were 
collected in a time course (Figure 1).  They observed that there was an increase in the 
expression of efflux pumps in the resistant strains (PEREA et al. 2001). 
 
Figure 1.  Schematic of sample collection done to study changes in the drug resistant 
strains.   
Recently, all of the strains reported in the paper were subjected to genomic sequencing 
at the Broad Institute in order to identify genes showing recurrent single nucleotide 
polymorphism (SNPs) in the evolved strain compared to the progenitor.  Some of the 
genes showing polymorphism in the evolved strains but not the progenitors are the 
genes that we identified in the screen (Chapter 4) except for orf19.6713.  The SNPs in 
genes of interest (described in Chapter 4) were also observed in recurrent cases. 
 In order to characterize these clinical isolates, especially in a tractable host, we 
performed a C. elegans survival assay in which we followed up 3 sets of samples 
(showing SNPs in our gene of interests) that are listed in Table 1(modified from Perea 
et. al. 2001) below.  In table 1, first isolate in each set of sample (e.g. 1649 in patient no. 
43) is the progenitor strain followed by the evolved strain in the time cour
stands for Minimum Inhibitory Concentration of the drug.   Clinical isolates 1, 12 and 13 
were from a time course used in a separate study 
isolates were also characterized using an 
 
 
 
The adhesion and survival assays were performed as mentioned before.  Germ tube 
formation assay was performed as follows:  Overnight cultures of the strains were 
grown in YPD at 30oC.  Next day, 0.05 OD
of fresh RPMI media + 10% FBS.   A 10 µl sample was immediately placed on a slide, 
observed and photographed for (t=0min).  Micrographs were then taken at every half 
hour interval.  For convenience purposes only 0 and 2 hour pictures are shown.
 
(WHITE 1997b)
in vitro assay. 
600nm were collected and resuspended in 3ml 
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Figure 2.  Germ tube formation (shown by white arrows) in some cases is affected in 
the evolved strain compared to progenitor.  SC5314 was used as a control. Cultures 
were grown in filament inducing media containing 10% FBS and pictures were taken at 
t=0 min and t=120 min.  Panels (A) 1649(P) and 3034(E), (B) 3917(P) and 4617(E1) 
and 4639(E2), (C) 5106(P) and 5108(E) and (D) Clinical Isolates 1, 12 and 13, are 
samples from different patients.  Altered in germ tube formation is observed between in 
the evolved strains when compared to the progenitors.  Though strains 4617(E1) and 
4639(E2) are hyper filamentous.  
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Figure 3.  Evolved strains are more adhesive on a polystyrene surface than their 
respective progenitor.  edt1-/- is the positive control and SC5314 is the negative control 
for the Adhesion Assay.  P is progenitor and E is evolved strain. The evolved strains are 
shown immediately after their respective progenitor strains. (A) Photograph taken of the 
crystal violet adhesion plate.  Strains are in the same order as shown in the graph. (B) 
Graph depicting the average of OD 590nm values taken from 8 wells for each strain.  
Except for, comparison between SC5314-3917 and SC5315-Clinical Isolate 1, all other 
comparisons (SC5314 with other strains and Progenitors with the Evolved) by Student’s 
t-test had p<0.01.   
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Figure 3.  Evolved strains show increased virulence in the worms compared to their 
respective progenitors.  Survival assays were performed along with SC5314, a 
laboratory wild type strain as control, for each group of strains  (A) 1649(P) and 3034(E) 
(B) 3917(P) and 4617(E1) and 4639(E2) and (C) 5106(P) and 5108(E).  All the evolved 
strains killed the worms significantly faster than their respective progenitors.  Log rank 
statistical analysis for the comparison between all progenitor and respective evolved 
strains had p<0.05.  Kelly Pastor performed the experiment in panels A and B. I am 
responsible for performing experiment in panel C, designing all the experiments and 
analyzing the data. 
B A 
C 
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From the germ tube formation (Figure 2), adhesion (Figure 3) and survival criteria 
(Figure 4) it is quite clear that the evolved strains do show an enhanced phenotype than 
their respective progenitors.  Thus the changes taking place in these strains through 
their evolution in the human host due to exposure to antifungal drugs does not seem to 
be restricted to the genes involved in antifungal resistance but seem to make the strain 
overall even more virulent.  Additional experiments needs to be performed in order to 
corroborate this.  Especially for 4617(E1) and 4639(E2), the results are interesting as 
they are also causing more adhesion and kill the worms faster than even SC5314.  Also 
note that survival experiments have been performed only once and need to be repeated 
again to reconfirm the data. 
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